

# **Predictors of COVID-19 vaccine acceptance across time and countries**

**PREPRINT – NOT PEER REVIEWED**

John R. Kerr<sup>1,2</sup>, Claudia R. Schneider<sup>1,2</sup>, Gabriel Recchia<sup>2</sup>, Sarah Dryhurst<sup>1,2</sup>, Ullrika Sahlin<sup>3</sup>, Carole Dufouil<sup>4,5</sup>, Pierre Arwidson<sup>6</sup>, Alexandra L. J. Freeman<sup>2</sup>, and Sander van der Linden<sup>1,2</sup>

<sup>1</sup> Department of Psychology, School of Biological Sciences, University of Cambridge,  
Downing Street, CB2 3EB Cambridge, UK.

<sup>2</sup> Winton Centre for Risk and Evidence Communication, University of Cambridge,  
Wilberforce Road, CB3 0WA Cambridge, UK.

<sup>3</sup> Center of Environmental and Climate Sciences, Lund University, Sölvegatan 37,  
SE-223 62 Lund, Sweden

<sup>4</sup> Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219,; Inserm,  
CIC1401-EC, 33000 Bordeaux, France

<sup>5</sup> Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000  
Bordeaux, France.

<sup>6</sup> Santé publique France, 94410 Saint-Maurice, France

## **Abstract**

Understanding the drivers of vaccine acceptance is crucial to the success of COVID-19 mass vaccination campaigns. Across 25 national samples from 12 different countries we examined the psychological correlates of willingness to receive a COVID-19 vaccine (total N = 25,334), with a focus on risk perception and trust in a number of relevant actors, both in general and specifically regarding the COVID-19 pandemic. Male sex, trust in medical and scientific experts and worry about the virus emerge as the most consistent predictors of reported vaccine acceptance across countries. In a subset of samples we show that these effects are robust after controlling for attitudes towards vaccination in general. Our results indicate that the burden of trust largely rests on the shoulders of the scientific and medical community, with implications for how future COVID-19 vaccination information should be communicated to maximize uptake.

## **Introduction**

COVID-19 has resulted in over a million deaths globally, illness for millions more, and unprecedented social and economic disruption<sup>1,2</sup>. Many governments have signaled that mass vaccination against the virus is the most straightforward—and possibly only—route to normality and stability<sup>3,4</sup>. While recent announcements of effective vaccines<sup>5,6</sup> are promising, the wider impact of vaccines on preventing the spread of disease is also dependent on the uptake within a given population. In order to achieve ‘herd immunity’, enough people in a population must be immune to prevent the spread of a disease among non-immune individuals. The proportion varies depending on a number of factors including how infectious the contagion is, its prevalence in a population, and the variation in individual susceptibility or exposure to infection<sup>7</sup>. Estimates for the level of immunity required for COVID-19 herd immunity have ranged from 50% to 80% of the population, acquired through either natural infection and recovery, or through vaccination<sup>8,9</sup>.

Vaccine hesitancy—defined as a delay in acceptance or refusal of vaccines despite availability<sup>10</sup>—poses a challenge to achieving herd immunity. If a sufficient number of people in a population reject vaccination—and herd immunity is not achieved—the virus will continue to circulate among susceptible individuals, including those who are unable to be vaccinated for medical reasons. The WHO identified vaccine hesitancy as one of the top 10 threats to global health in 2019<sup>11</sup>, and in the pressing context of COVID-19, understanding vaccine hesitancy has only grown in importance<sup>12</sup>.

Public health researchers concerned with uptake of vaccination have understandably sought to uncover the drivers of vaccine hesitancy. By identifying antecedents of vaccine hesitancy, policy makers, public health officials, and professional communicators can target interventions to increase uptake of vaccines and ultimately reduce the burden of disease in a population<sup>4</sup>. However, strategies developed for campaigns targeting diseases with well-established vaccines (e.g. MMR, pertussis) may not fully translate to a pandemic context where there is greater uncertainty, less information available, and where institutional trust plays a greater role—as was noted in the wake of the 2009 H1N1 influenza pandemic<sup>13</sup>.

Recent evidence shows that acceptance of a COVID-19 vaccine is far from universal in many countries. Lazarus et al<sup>14</sup> conducted a series of surveys across 19 countries in June 2020, asking respondents how much they agreed with the following statement: ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’. The proportion of respondents who agreed ranged from 88.6% (China) to 55.8% (Russia). Examining possible predictors of vaccine acceptance, the authors report that men, older people, and those who express greater trust in the government were more likely to express willingness to receive a vaccine. The role of trust (in science, the government or the medical system) is a recurring theme in many other recent studies which have examined COVID-19 vaccine hesitancy in individual countries<sup>15–20</sup>. For example, Palamenghi et al<sup>20</sup> report that across two large random samples of the Italian population, trust in science was positively correlated ( $r = .37$ ) with willingness to receive a COVID-19 vaccine. Frank and Arim<sup>16</sup> report that Canadians who are more trusting of local and national government bodies are more likely to express intentions to receive a vaccine if available, as are those who report high general social trust (i.e. believing that ‘most people can be trusted’).

Such results align with pre-COVID studies which have highlighted the role of trust in vaccination intentions and attitudes<sup>13,21,22</sup>. However, we note that recent studies examining

COVID-19 vaccine intentions have typically only examined trust in one entity (e.g. government or hospitals); research to date has not considered the possible overlap between trust in the government, trust in science and medicine, and general social trust<sup>23-25</sup>. There is also a question over the extent to which vaccine acceptance is linked to mistrust in experts and authorities *regarding COVID-19 in particular*, or a more general lack of trust in these actors. In order to target communications specifically designed to satisfy the information needs of those who distrust official authorities, it is important to identify the precise agents that they distrust (and, ideally, why).

Beyond trust, the perceived threat or risk posed by a given disease has also been shown to predict vaccination attitudes. Models of health behavior, such as the Health Belief Model<sup>26</sup> and Protection Motivation Theory<sup>27</sup>, place the perceived risk or severity of a disease as a key driver of vaccination intentions (and other preventative health behaviors)<sup>13,28</sup>. Recent surveys in the US, Malaysia, and Israel have shown that perceived risk and worry regarding the COVID-19 virus is associated with vaccine acceptance<sup>29-31</sup>. Other factors, such as the perceived benefits and costs as well as efficacy of protective behaviors are also outlined in models of health behavior as predictors of engagement in a given health behavior. However, until recently, little information about the possible costs, distribution and efficacy of a COVID-19 vaccine was available, meaning that the public has not generally been able to assess the potential benefits of a vaccine outside of a purely hypothetical arena (although experimental work has examined the influence of these factors on willingness to receive a vaccine<sup>32</sup>).

There are also increasing concerns about the politicization of science and about politics becoming entangled with vaccine beliefs and attitudes specifically, particularly in the context of a pandemic where central government structures are deeply involved in all stages of the public health response<sup>13,33</sup>. Prior research<sup>34</sup> has shown that the rhetoric adopted by

political elites on social media can fuel anti-vaccination attitudes amongst their followers and that ideologies can help explain anti-vaccination attitudes<sup>30,35</sup>.

In the current study we present a more comprehensive international analysis of the role of key social, political, and psychological predictors of COVID-19 vaccine acceptance across 12 countries, with multiple national surveys in some countries (total  $N = 25,334$ , see Table 1). All samples were recruited via online panel providers using quotas to ensure samples were matched to the general population in terms of age and gender (with the exception of France, see methods). Unlike previous studies, we examine reported trust in a range of actors, both in general and specifically relating to the COVID-19 pandemic. We also include several demographic factors (including politics), numeracy (known to play a role in risk perceptions<sup>36</sup>, and vaccine attitudes in particular<sup>37</sup>), affective (worry) and cognitive (perceived likelihood of infection) aspects of perceived COVID-19 risk<sup>38</sup>, broad measures of perceived efficacy, and, in a subset of samples, general attitudes towards vaccines.

## **Methods**

### *Participants and procedure*

Between March and October 2020, we fielded 25 separate surveys across 12 countries. The majority of samples were recruited through an ISO certified international survey company Respondi (respondi.com). Participants in Australia were recruited through Dynata (dynata.com), and additional US and UK samples were recruited via Prolific (prolific.ac). Quota-based sampling ensured all samples were representative of the country population in terms of age and gender, and, in Prolific samples, ethnicity<sup>39</sup>. Participants who had previously completed a survey were prevented from completing further surveys, so all our samples represent different individuals. Demographic details for each sample are shown in Table 1. For completeness we include several samples in which vaccine acceptance was

measured, but the survey did not always include all the predictor variables used in models presented below. Surveys which did not include all predictor variables are marked with a ‘\*’ in Table 1.

All participants were directed via a study link to the Qualtrics platform, and provided informed consent before completing the survey. This study was overseen by the University of Cambridge Psychology Research Ethics Committee (PRE.2020.034).

### *Materials*

Participants reported their age and gender, level of education (ranging from *No formal education above age 16 to PhD*), and political orientation (*Very liberal/left wing to Very conservative/right wing*). Numeracy was measured as a combined index of the 2-3 item adaptive form of the Berlin Numeracy Test<sup>40</sup> and an additional risk literacy item from Lipkus et al.<sup>41</sup>.

Participants completed a widely used measure of general social trust (*Generally speaking, would you say most people can be trusted, or that you can't be too careful in dealing with people?*)<sup>42</sup> and a separate measure of prosociality (*To what extent do you think it's important to do things for the benefit of others and society even if they have some costs to you personally?*). Trust in experts and trust in government were each measured as the combined average of reported trust in three targets (experts: scientists, medical doctors and nurses, and scientific knowledge [Cronbach's  $\alpha$  .77-.86]; government: politicians, current government, civil servants [ $\alpha$  .73-.90]; all from *Cannot be trusted at all to Can be trusted a lot*). We also asked participants to report their trust in several actors with specific regard to the COVID-19 pandemic. Participants reported the extent to which they trust politicians in their country to ‘deal effectively with the pandemic’, and how much they separately trusted the country’s national scientific and medical advisors, independent experts not connected

with government, and the WHO to ‘know the best measures to take in the face of the pandemic’ (all from *Not at all* to *Very much*). Personal and government efficacy were captured by items asking participants the extent to which they felt that, respectively, their own actions, and the actions of their country ‘to limit the spread of coronavirus can make a difference’ (*Not at all* to *Very much*). Perceived likelihood of infection was measured as an index of three related items (example: *I will probably get sick with the coronavirus/COVID-19*;  $\alpha$  .71-.89). Participants also reported their level of worry about the virus (from *Not at all worried* to *Very worried*). In a subset of UK samples, we also asked participants about their general attitude towards vaccination, using two items from Lewandowsky et al.’s<sup>35</sup> scale (example: *I believe that vaccines are a safe and reliable way to help avert the spread of preventable diseases* [ $r$ s .83-.87]).

Participants’ vaccine acceptance was measured with the question: ‘*If a vaccine were to be available for the coronavirus/COVID-19 now, would you get vaccinated yourself?*’ (*Yes/No*). Participants were also asked ‘*If a vaccine were to be available for the coronavirus/COVID-19 now: Would you recommend vulnerable friends/family to get vaccinated?*’ (*Yes/No*). Full item wording for all measures can be found in Table S1.

Surveys were translated from English to other languages by native speakers fluent in English. Multi-item scales (trust in science, trust in government and perceived likelihood of infection) were subjected to multi-group confirmatory factor analysis to establish measurement invariance<sup>43</sup>. All scales exhibited metric invariance based on a criterion of a reduction in CFI no greater than .02 when constraining item factor loadings to be equal across different countries (see Table S2). This more relaxed criterion (compared to the widely used  $\Delta\text{CFI} < .01$ <sup>43</sup>) was applied in light of the recommendations of Rutkowski and Svetina<sup>44</sup> for analyses with a large number of groups. Metric invariance indicates that effects of the construct in question (but necessarily not latent means) can be compared across groups.




## Results

Figure 1 shows the percentage of participants in each survey who responded that they would be willing to be vaccinated if a COVID-19 vaccine was available, or would recommend a vaccine to vulnerable others, given the options of ‘Yes’ or ‘No’<sup>1</sup>. Across all samples, the percentage of respondents who stated they were willing to receive a vaccine ranged from 62.6% (Sweden, April) to 88.1% (Mexico, March), while the percentage of those who said they would recommend a vaccine to vulnerable others ranged from 67.5% (US, September) to 91.7% (UK, March). Descriptively, in every single sample the proportion of respondents stating a willingness to receive a vaccine was lower than the proportion who would recommend it to vulnerable others ( $M_{diff} = -5.79\%$ ,  $SD = 3.00$ ). We also note a trend of decreasing stated acceptance over time: in nearly all countries with multiple samples, vaccine acceptance in any given survey was lower than previous surveys of the same population. For example between March and May, 2020, stated vaccine acceptance among respondents in Mexico dropped from 88.1% to 73.9% (a two-sample proportion test indicated that this difference was statistically significant, 95%CI [-18.4%, -9.9%],  $z = 6.51$ ,  $p < .001$ ) In the US, stated vaccine acceptance (among participants recruited through online panel provider Respondi) fell more than 12 percentage points, from 74.7% to 62.6%, between May and September, 2020 (95%CI [-16.7%, -7.5%],  $z = 5.09$ ,  $p < .001$ )

---

<sup>1</sup> Based on respondents who answered the question. In the Italy sample a number of participants were not presented with these items due to a technical error ( $n = 80$ , 11%). In the remaining samples the average proportion of missing responses for vaccine intention and recommendation items was 1%.



**Figure 1. COVID-19 vaccine acceptance across countries and time.** Percentage of respondents who stated they were willing to receive or recommend a COVID-19 vaccine across surveys. UK and US samples using different panel providers are reported separately.

Table 1.


Sample demographics and percentage of participants willing to receive a COVID-19 vaccine or to recommend it to vulnerable friends/family.

Country	Source	Date	N	M <sub>Age</sub> (SD)	Female (%)	Tertiary Educated (%)	Vaccine - acceptance (%)	Vaccine - recommend (%)
Australia	Dynata	20-Mar	700	46.3 (16.4)	51.0	43.4	82.9	88.7
China*	Respondi	09-Apr	700	43.2 (14.3)	48.9	73.1	85.8	87.4
Germany	Respondi	23-Mar	700	46.6 (16.0)	49.9	32.7	80.8	89.2
Spain	Respondi	22-Mar	700	46.6 (15.0)	51.1	58.1	83.6	89.8
Spain	Respondi	06-May	700	46.0 (15.0)	50.4	57.0	79.8	82.5
France*	BVA	03-Apr	3002	48.8 (16.5)	47.5	71.1	69.7	80.7
Italy	Respondi	22-Mar	700	46.9 (26.1)	50.4	41.3	85.3	88.2
Japan	Respondi	10-Apr	699	48.1 (16.4)	50.9	53.3	74.5	80.1
S. Korea	Respondi	09-Apr	700	45.3 (15.5)	49.0	70.5	85.6	88.4
Mexico	Respondi	21-Mar	693	38.4 (14.2)	50.5	66.4	88.1	90.3
Mexico	Respondi	06-May	700	38.7 (14.6)	51.0	75.8	73.9	75.6
Sweden	Respondi	28-Mar	700	48.4 (77.3)	49.1	40.3	66.3	77.2
Sweden	Respondi	17-Apr	700	45.3 (16.7)	48.9	40.2	63.4	73.7
UK	Prolific	19-Mar	703	45.6 (15.7)	50.9	53.9	80.4	91.7
UK	Prolific	07-May	1157	45.2 (23.1)	50.7	56.5	80.4	86.7
UK	Prolific	06-Jul	1325	44.8 (17.5)	52.5	58.5	78.9	85.3
UK	Prolific	18-Sep	1869	38.1 (15.0)	51.2	56.2	73.0	79.5
UK	Respondi	07-May	1150	45.6 (16.0)	52.0	43.4	78.9	84.2
UK*	Respondi	08-Jun	500	45.9 (15.9)	53.2	39.7	79.0	83.2
UK	Respondi	06-Jul	1326	46.0 (24.4)	51.7	44.9	80.1	84.4
UK	Respondi	18-Sep	1855	45.7 (19.6)	51.6	42.6	75.7	79.9
UK	Respondi	29-Oct	1744	47.1 (23.4)	52.2	42.0	72.2	76.1
US	Prolific	19-Mar	702	45.1 (15.9)	50.6	66.8	75.7	85.7
US	Respondi	07-May	700	45.7 (26.5)	51.0	59.3	74.7	80.1
US*	Respondi	28-Sep	909	44.8 (15.6)	50.6	50.1	62.6	67.5

\*Indicates survey that included vaccine acceptance items but not all model predictor variables (excluded from analyses below).

We fitted a logistic regression model to data from each sample to identify the correlates of COVID-19 vaccine intentions. Predictors included: demographic variables; an objective measure of numeracy, political ideology; general social trust; prosociality (willingness to ‘do things for the benefit of others and society’ even at personal cost); general trust in medical and scientific experts; general trust in government; specific trust in politicians to manage the pandemic; specific trust in (separately) national science advisors,

independent scientists and the WHO to ‘know the best measures to take in the face of the pandemic’; the perceived efficacy of their own and their country’s actions to limit the spread of the virus; perceived likelihood of infection; and, worry about COVID-19 (for details on measures see Methods section and Table S1; descriptive statistics are reported in Tables S3 and S4, and bivariate correlations in Figure S1). Continuous measures (i.e. all except gender) were scaled and mean centered prior to analysis. Multicollinearity analyses indicated no issues arising from correlated predictors (all variance inflation factor values  $< 4$ ). To facilitate the interpretation of results we present odds ratios in a heat map format in Figure 2. A full table of model results including confidence intervals can be found in Tables S5 and S6. Results of models predicting vaccine recommendation responses are also presented in supplementary materials (Figure S2, Tables S7 and S8).



**Figure 2. Predictors of vaccine acceptance.** Heatmap of odds ratios in logistic regression model predicting stated vaccine acceptance. Columns represent individual samples and rows represent predictors in model. Grey values are non-significant,  $p > .05$ . Red shading indicates a lower likelihood of reported vaccine acceptance and blue shading a higher likelihood. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific).

Considering the most consistent predictors of stated vaccine acceptance across samples, we find that in most samples individuals who report a higher level of general trust in experts ( $OR_{pooled} = 1.27$ , 95%CI [1.22, 1.33]), or who are more worried about the virus ( $OR_{pooled} = 1.49$ , [1.43, 1.55]), are more likely to say that they would accept a vaccine. In Germany, Spain, Mexico, Sweden (March only), and nearly all UK samples, females are generally less likely to say that they would accept a COVID-19 vaccine if available ( $OR_{pooled} = 0.59$ , [0.55, 0.64])<sup>2</sup>. We also note that measures of efficacy, both at the personal ( $OR_{pooled} = 1.01$ , [0.97, 1.06]) and country level ( $OR_{pooled} = 1.01$ , [0.96, 1.07]), were not significantly associated with reported vaccine acceptance in most samples.

Our results reveal a great deal of heterogeneity in the relevance of predictors across countries, but also across time in countries where we conducted multiple surveys. For example, in the United States only a few consistent predictors emerged. Most notably, political conservatism was associated with a lower likelihood to accept a COVID-19 vaccine ( $OR_{USA-Mar} = 0.73$  [0.57, 0.93];  $OR_{USA-May} = 0.75$ , [0.57, 0.99]) whereas trust in experts ( $OR_{USA-Mar} = 1.53$  [1.16, 2.03];  $OR_{USA-May} = 1.38$ , [1.03, 1.84]) and personal worry about the virus ( $OR_{USA-Mar} = 1.48$  [1.17, 1.87];  $OR_{USA-May} = 1.27$ , [0.99 – 1.64]) were associated with increased vaccination intentions. In contrast, in the United Kingdom, additional factors such as the role of age, gender, and prosociality played a significant role. There was also variation over time. For example, although political ideology was not a significant predictor in the UK in May or July, conservatism was associated with lower vaccination intentions from September onwards (ORs 0.84-.88), which may be related to increased polarization. To illustrate the increasing strength of the association between political ideology and vaccine


---

<sup>2</sup> UK data was over represented in our pooled sample. As a robustness check we also fitted the model to the pooled sample with UK data removed and report that the effects of gender, trust in experts and worry remain significant ( $ps < .001$ ; see Table S5).

acceptance over time in the UK, in Figure 3 we plot the predicted likelihood of reported vaccine acceptance across the political spectrum (holding all other predictors constant).

In the UK, we also report a different pattern of effects when comparing between samples collected via different providers, even where these were collected on the same day (in May, July, and September), were matched on age and gender, and controlling for a range of other demographic variables. This underscores the caution that must be applied when studies generalize results from a single survey sample (particularly an online survey).

In terms of variance explained, the variables in our model explained approximately 10-30% of the variance in the likelihood of vaccine acceptance vs refusal, with the exception of samples recruited in Korea (4%) and Japan (8%).



**Figure 3. Political ideology and vaccine acceptance in the UK.** Predicted likelihood that an individual will accept being vaccinated at varying levels of political ideology (1 = very liberal/left wing, 7 = very conservative/right wing) in UK samples over time.

### *Accounting for general vaccine attitudes*

To examine the extent to which the effects in our model can be accounted for by a negative perception of vaccines in general, we conducted an additional set of analyses. In our three most recent UK surveys we included a two-item measure of general vaccine attitudes (adapted from Lewandowsky et al.<sup>35</sup>). A comparison of results from models with or without general vaccine attitudes as a predictor is shown as a heat map in Figure 4. Although attitudes toward vaccination increase the explained variance of our model ( $\Delta R^2$  4%-9%) and reveal strong significant effects such that more positive attitudes are associated with increased vaccination intentions (ORs 1.69-2.31; full results in Table S9), the relationships in the original model appear robust and are only minimally attenuated when accounting for generalized attitudes.



	Base model			Including general vaccine attitudes		
	UK_P (Sep)	UK_R (Sep)	UK_R (Oct)	UK_P (Sep)	UK_R (Sep)	UK_R (Oct)
Age	1.12	1.48	1.60	1.16	1.40	1.41
Gender (Female)	0.61	0.50	0.44	0.62	0.49	0.44
Education	1.02	1.11	1.18	1.00	1.07	1.15
Numeracy	1.11	1.00	1.00	1.05	0.93	0.87
Politics (Conservative)	0.84	0.38	0.86	0.85	0.36	0.84
Prosociality	1.11	1.09	1.07	1.10	1.08	1.04
General social trust	1.03	1.09	0.97	1.03	1.04	0.96
General trust: Experts	1.39	1.24	1.45	1.29	1.11	1.29
General trust: Govt	1.27	1.13	1.02	1.24	1.15	0.98
COVID trust: Politicians	0.94	1.12	1.26	0.95	1.18	1.37
COVID Trust: National sci/med advisors	1.13	1.25	1.29	1.11	1.14	1.21
COVID Trust: Independent scientists	0.93	0.38	1.00	0.95	0.39	0.96
COVID Trust: WHO	1.45	1.33	1.03	1.41	1.33	1.02
Personal efficacy	1.10	1.03	1.03	1.06	1.00	0.98
Govt efficacy	1.01	0.95	1.04	1.01	0.95	1.08
Perceived infection risk	1.04	1.08	0.98	1.02	1.12	0.96
Worry about COVID	1.36	1.56	1.44	1.36	1.46	1.41
General vaccine attitudes				1.69	2.10	2.31
Tjur $R^2$	0.19	0.17	0.19	0.23	0.25	0.28

**Figure 4. Negative general attitudes towards vaccination do not fully account for relationships in the model.** Results of logistic regression models predicting reported COVID-19 vaccine acceptance in UK samples, excluding (left panel) or including (right panel) general vaccine attitudes as a predictor. Odds ratios shown are based on scaled predictors (other than gender). Grey values are non-significant,  $p > .05$ . For space, samples are defined by a letter denoting participant source (R, Respondi; P, Prolific).

## Discussion

Understanding the psychological determinants of vaccine acceptance and hesitancy is crucial during a global pandemic. Across all countries surveyed, between March and September 2020, a substantial proportion of participants (up to 37% in some countries) said that they would *not* accept a hypothetical COVID-19 vaccine. People were slightly more likely to say that they would recommend it to vulnerable friends and family members. Considering who is more or less likely to report willingness to be vaccinated against COVID-19, being male, expressing general trust in those with scientific or medical expertise, and worrying about the virus are the most consistent correlates of vaccine acceptance across our samples. It is important to note that hesitancy about a COVID-19 vaccine is not purely attributable to people's attitudes to vaccines in general. Although (in the UK, where we studied it) negative attitudes towards vaccines in general are a significant and important predictor of COVID-19 vaccine refusal, there are clearly additional factors at play in determining public reactions to a COVID-19 vaccine. This broadly aligns with other research indicating that, for many people, there are concerns specifically around the rapid and novel development processes of COVID-19 vaccines and possible safety issues<sup>29,45</sup>. Our multivariate analyses show that the bulk of the burden of trust rests on science and medicine. Accounting for the other factors in our model, we find that trust in government (both generally and regarding COVID-19) and general social trust (i.e. trust in people) are *not* significantly associated with vaccine acceptance in most of our samples.

The fact that we saw only a weak link between stated vaccine acceptance and our measure of prosociality—along with the fact that higher numbers of people said that they'd recommend the vaccine to a vulnerable friend or relative than say they would accept it themselves—suggests that the prosocial nature of vaccines may not be recognized by many people. Recent experimental research has shown that emphasizing the societal benefits of

herd immunity (i.e., the need for those who do not see themselves as personally vulnerable to take the vaccine in order to provide protection for those who are) may assist uptake<sup>46</sup>.

The higher reluctance from women to say that they would take a vaccine is in line with other work focusing on acceptance of a potential COVID-19 vaccine<sup>14,15</sup>, and vaccination generally<sup>22</sup> but has not been adequately explained. Even when general vaccine beliefs are taken into account, however, the gender bias remains. Qualitative work should focus on investigating this further, in order to understand the root of women's concerns about the COVID-19 vaccine. We see very little effect of our measures of personal or governmental efficacy, but this may be related to the fact that a vaccine against COVID-19 was hypothetical at the time of the surveys and our measures did not directly ask about vaccination.

Another important finding highlighted by our repeated samples is that vaccine acceptance appears to be politicized in the US and is becoming so in the UK. Our US results agree with previous US research focusing on COVID-19 vaccine acceptance<sup>32,47</sup>, which noted that political conservatives are less accepting of potential COVID-19 vaccines. Our UK results align with those of Maher et al, who, through network analysis, show a pattern of attitudinal alignment over time in a small UK sample, resulting in the emergence of a politically conservative faction expressing less trust in scientists, doctors, and vaccines<sup>17</sup>. Although international research has suggested that political conservatism is correlated with anti-vaccination attitudes globally<sup>33</sup>, we did not find that ideology was associated with vaccine acceptance outside of the US and UK. However most other countries were only surveyed in earlier stages of the pandemic (i.e. prior to May, 2020) and we can therefore not say whether they might have followed a similar pattern to the UK as time went on.

It is possible that misinformation susceptibility<sup>48,49</sup> and conspiracy thinking<sup>50</sup> underlie the association between ideology and vaccine attitudes to some extent. For example, Motta et al.<sup>51</sup> find that far right-wing media outlets have disproportionately spread misinformation during the early stages of the pandemic. Susceptibility to misinformation around COVID-19 was also found in prior research to be associated with measures of vaccine hesitancy<sup>49</sup>. There is already a proliferation of conspiracy theories focused on specific COVID-19 vaccines<sup>52,53</sup>. It will be important to tackle these pro-actively through ‘prebunking’ methods to inoculate against misinformation<sup>54,55</sup>.

Finally, we acknowledge that the heterogeneity in our results across time and countries highlights the role that (unmeasured) contextual, country-specific factors play in informing individuals’ vaccination attitudes. As noted by the WHO SAGE working group on vaccine hesitancy, individual factors such as trust and risk perception intersect with contextual influences such as culture, media environments, and information from local leaders<sup>10</sup>. Lastly, our samples were not truly representative of the general population in each country: although they were quota-balanced on gender and age, the population that respond to an online questionnaire will differ from the general population on several significant characteristics. However, the rank ordering of countries on vaccine acceptance in our study is similar to that of Lazarus et al<sup>10</sup>, which were based on a random stratified sampling approach using several online panel providers. This gives us some confidence in the generalizability of our results, and the fact that our samples were generally larger and included more trust-focused questions makes them useful for exploring these important predictors of vaccine attitudes.

In terms of practical considerations, our finding that trust in scientific and medical institutions is one of the strongest predictors of vaccine acceptance highlights the need to work proactively with others from outside of this sphere, such as community and religious

leaders<sup>56</sup> to open a two-way conversation with those who distrust the scientific and medical establishment. Due consideration must also be given to the accessibility<sup>57</sup>, format<sup>58,59</sup>, and transparency<sup>60,61</sup> of information provided to the public. Future research should continue to evaluate how to most effectively communicate evidence about vaccination, and should seek to more deeply understand the concerns and needs of those who express hesitancy regarding COVID-19 vaccination. As Bhopal<sup>62</sup>, commenting on potential COVID-19 mass vaccination efforts, writes, “Open, honest, factual and sensitively conducted public dialogue is now urgent.”

## **Conclusions**

Countries around the world face a major evidence communication challenge when it comes to the COVID-19 vaccines that are about to become available. In order to reach a large enough proportion of the population in each country to achieve herd immunity, it is vital to increase in the number of people who are willing to take a vaccine. To achieve this, non-pharmaceutical interventions will need to be deployed<sup>63</sup>, such as communicating trustworthy information about the vaccines via credible sources. In the current research, we have demonstrated across 12 national samples that people’s level of worry about COVID-19 and their trust in experts and medical and scientific institutions are key determinants of potential vaccine acceptance. Future research should confirm these findings in experimental settings. We recommend that empirical studies should continue to be carried out alongside qualitative work with different communities to get a rounded understanding of people’s concerns and misunderstandings. Only by knowing these can we adequately address them and provide people with the information they need to make a decision that will affect not just their own health, but that of their community as well.

### **Data availability**

The data and analysis code for this study are available at:

[https://osf.io/vgez2/?view\\_only=8fe81f5fe3f345a99b06edeaba6bd9e1](https://osf.io/vgez2/?view_only=8fe81f5fe3f345a99b06edeaba6bd9e1)

### **Acknowledgments**

This study was funded by the Winton Centre for Risk and Evidence Communication which is supported by the David and Claudia Harding Foundation. We would like to thank María del Carmen Climent Palmer, Ban Mutsuhisa, Jin Park, and Giulia Luoni for additional translations, the University of Tokyo for their collaboration, and all the participants and those who helped to administer the study.

## References

1. Rodríguez Mega, E. COVID has killed more than one million people. How many more will die? *Nature* (2020) doi:10.1038/d41586-020-02762-y.
2. International Monetary Fund. *World Economic Outlook, October 2020: A Long and Difficult Ascent*. (2020).
3. Lytras, T. & Tsiodras, S. Lockdowns and the COVID-19 pandemic: What is the endgame? *Scandinavian Journal of Public Health* (2020) doi:10.1177/1403494820961293.
4. Schoch-Spana, M. *et al.* The public's role in COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States. *Vaccine* (2020) doi:10.1016/j.vaccine.2020.10.059.
5. Callaway, E. What Pfizer's landmark COVID vaccine results mean for the pandemic. *Nature* (2020) doi:10.1038/d41586-020-03166-8.
6. Callaway, E. COVID vaccine excitement builds as Moderna reports third positive result. *Nature* **587**, 337–338 (2020).
7. Gomes, M. G. M. *et al.* Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. *medRxiv* (2020) doi:10.1101/2020.04.27.20081893.
8. Sanche, S. *et al.* High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg. Infect. Dis.* **26**, 1470–1477 (2020).
9. Fontanet, A. & Cauchemez, S. COVID-19 herd immunity: where are we? *Nat. Rev. Immunol.* **20**, 583–584 (2020).
10. WHO. *Report of the Sage Working Group on Vaccine Hesitancy*. (2014).
11. WHO. Ten threats to global health in 2019. (2019).
12. Verger, P. & Dubé, E. Restoring confidence in vaccines in the COVID-19 era. *Expert Review of Vaccines* (2020) doi:10.1080/14760584.2020.1825945.
13. Mesch, G. S. & Schwirian, K. P. Social and political determinants of vaccine hesitancy: Lessons learned from the H1N1 pandemic of 2009-2010. *Am. J. Infect. Control* **43**, 1161–1165 (2015).
14. Lazarus, J. V. *et al.* A global survey of potential acceptance of a COVID-19 vaccine. *Nat. Med.* (2020) doi:10.1038/s41591-020-1124-9.
15. Wang, J. *et al.* Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. *Vaccines* **8**, 482 (2020).
16. Frank, K. & Arim, R. Canadians' willingness to get a COVID-19 vaccine when one becomes available: What role does trust play? *Statistics Canada* (2020).
17. Maher, P. J., MacCarron, P. & Quayle, M. Mapping public health responses with attitude networks: the emergence of opinion-based groups in the UK's early COVID-19 response phase. *Br. J. Soc. Psychol.* **59**, 641–652 (2020).
18. Padhi, B. K. & Almohaithef, M. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. *medRxiv* 2020.05.27.20114413 (2020) doi:10.1101/2020.05.27.20114413.
19. Soveri, A., Karlsson, L. C., Antfolk, J., Lindfelt, M. & Lewandowsky, S. Unwillingness to

- engage in behaviors that protect against COVID-19: Conspiracy, trust, reactance, and endorsement of complementary and alternative medicine. doi:10.31234/OSF.IO/MHCTF.
20. Palamenghi, L., Barello, S., Boccia, S. & Graffigna, G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. *Eur. J. Epidemiol.* **35**, 785–788 (2020).
  21. Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L. & Ratzan, S. Addressing the vaccine confidence gap. *The Lancet* vol. 378 526–535 (2011).
  22. de Figueiredo, A., Simas, C., Karafillakis, E., Paterson, P. & Larson, H. J. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. *Lancet* **396**, 898–908 (2020).
  23. National Academies of Sciences, Medicine, and Engineering. *Trust and Confidence at the Interfaces of the Life Sciences and Society. A Workshop Summary.* (2015).
  24. Hartman, R. O., Dieckmann, N. F., Sprenger, A. M., Stastny, B. J. & DeMarree, K. G. Modeling attitudes toward science: Development and validation of the credibility of science scale. *Basic Appl. Soc. Psych.* **39**, 358–371 (2017).
  25. Brewer, P. R. & Ley, B. L. Whose science do you believe? Explaining trust in sources of scientific information about the environment. *Sci. Commun.* **35**, 115–137 (2013).
  26. Becker, M. H. The Health Belief Model and Sick Role Behavior. *Health Educ. Monogr.* **2**, 409–419 (1974).
  27. Rogers, R. W. A Protection Motivation Theory of Fear Appeals and Attitude Change. *J. Psychol.* **91**, 93–114 (1975).
  28. Ling, M., Kothe, E. J. & Mullan, B. A. Predicting intention to receive a seasonal influenza vaccination using Protection Motivation Theory. *Soc. Sci. Med.* **233**, 87–92 (2019).
  29. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur. J. Epidemiol.* **35**, 775–779 (2020).
  30. Kelly, B. *et al.* Predicting willingness to vaccinate for COVID-19 in the US. *JCH Impact* (2020).
  31. Wong, L. P., Alias, H., Wong, P.-F., Lee, H. Y. & AbuBakar, S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum. Vaccin. Immunother.* **16**, 2204–2214 (2020).
  32. Kreps, S. *et al.* Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw. open* **3**, e2025594 (2020).
  33. Hornsey, M. J., Harris, E. A. & Fielding, K. S. The Psychological Roots of Anti-Vaccination Attitudes: A 24-Nation Investigation. *Heal. Psychol.* **37**, 307–315 (2018).
  34. Hornsey, M. J., Finlayson, M., Chatwood, G. & Begeny, C. T. Donald Trump and vaccination: The effect of political identity, conspiracist ideation and presidential tweets on vaccine hesitancy. *J. Exp. Soc. Psychol.* **88**, 103947 (2020).
  35. Lewandowsky, S., Gignac, G. E. & Oberauer, K. The role of conspiracist ideation and worldviews in predicting rejection of science. *PLoS One* **8**, e75637 (2013).
  36. Reyna, V. F., Nelson, W. L., Han, P. K. & Dieckmann, N. F. How Numeracy Influences Risk Comprehension and Medical Decision Making. *Psychol. Bull.* **135**, 943–973 (2009).
  37. Betsch, C. *et al.* Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PLoS One* **13**, e0208601 (2018).



38. Jang, W. M. *et al.* Influence of trust on two different risk perceptions as an affective and cognitive dimension during Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea: Serial cross-sectional surveys. *BMJ Open* **10**, 33026 (2020).
39. Prolific. Representative Samples on Prolific.
40. Cokely, E. T., Galesic, M., Schulz, E., Ghazal, S. & Garcia-Retamero, R. Measuring Risk Literacy: The Berlin Numeracy Test. *Judgm. Decis. Mak.* **7**, 25–47 (2012).
41. Lipkus, I. M., Samsa, G. & Rimer, B. K. General Performance on a Numeracy Scale Among Highly Educated Samples. *Med. Decis. Mak.* **21**, 37–44 (2001).
42. Lundmark, S., Gilljam, M. & Dahlberg, S. Measuring Generalized Trust. *Public Opinion Quarterly* vol. 80 26–43 (2016).
43. Fischer, R. & Karl, J. A. A Primer to (Cross-Cultural) Multi-Group Invariance Testing Possibilities in R. *Front. Psychol.* **10**, 1507 (2019).
44. Rutkowski, L. & Svetina, D. Assessing the Hypothesis of Measurement Invariance in the Context of Large-Scale International Surveys. *Educ. Psychol. Meas.* **74**, 31–57 (2014).
45. Campbell, D. Protecting others and record of vaccines main reasons to get Covid jab, poll shows. *Guardian* (2020).
46. Betsch, C., Böhm, R., Korn, L. & Holtmann, C. On the benefits of explaining herd immunity in vaccine advocacy. *Nat. Hum. Behav.* **1**, 0056 (2017).
47. Carpiano, R. M. Demographic differences in US adult intentions to receive a potential coronavirus vaccine and implications for ongoing study. doi:10.1101/2020.09.07.20190058.
48. Calvillo, D. P., Ross, B. J., Garcia, R. J. B., Smelter, T. J. & Rutchick, A. M. Political Ideology Predicts Perceptions of the Threat of COVID-19 (and Susceptibility to Fake News About It). *Soc. Psychol. Personal. Sci.* **11**, 1119–1128 (2020).
49. Roozenbeek, J. *et al.* Susceptibility to misinformation about COVID-19 around the world. *R. Soc. Open Sci.* **7**, 201199 (2020).
50. Linden, S., Panagopoulos, C., Azevedo, F. & Jost, J. T. The Paranoid Style in American Politics Revisited: An Ideological Asymmetry in Conspiratorial Thinking. *Polit. Psychol.* pops.12681 (2020) doi:10.1111/pops.12681.
51. Motta, M., Stecula, D. & Farhart, C. How right-leaning media coverage of Covid-19 facilitated the spread of misinformation in the early stages of the pandemic in the U.S. *Can. J. Polit. Sci.* **53**, 335–342 (2020).
52. Reuters. Fact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna. *Reuters* (2020).
53. May, L. Antivaxxers share conspiracy theories after Pfizer announcement. *Daily Mail* (2020).
54. Roozenbeek, J., van der Linden, S. & Nygren, T. Prebunking interventions based on ‘inoculation’ theory can reduce susceptibility to misinformation across cultures. *Harvard Kennedy Sch. Misinformation Rev.* **1**, (2020).
55. Jolley, D. & Douglas, K. M. Prevention is better than cure: Addressing anti-vaccine conspiracy theories. *J. Appl. Soc. Psychol.* **47**, 459–469 (2017).
56. Jarrett, C., Wilson, R., O’Leary, M., Eckersberger, E. & Larson, H. J. Strategies for addressing vaccine hesitancy – A systematic review. *Vaccine* **33**, 4180–4190 (2015).
57. O’Neill, O. Accountability, trust and informed consent in medical practice and research. *Clin. Med. J. R. Coll. Physicians London* **4**, 269–276 (2004).

58. Schwartz, L. M., Woloshin, S. & Welch, H. G. Using a Drug Facts Box to Communicate Drug Benefits and Harms. *Ann. Intern. Med.* **150**, 516–527 (2009).
59. Brick, C., McDowell, M. & Freeman, A. L. J. Risk communication in tables versus text: A registered report randomized trial on ‘fact boxes’. *R. Soc. Open Sci.* **7**, (2020).
60. Blastland, M., Freeman, A. L. J., Linden, S. Van Der, Marteau, T. M. & Spiegelhalter, D. Five rules for evidence communication. *Nature* **587**, 362–364 (2020).
61. van der Bles, A. M., van der Linden, S., Freeman, A. L. J. & Spiegelhalter, D. J. The effects of communicating uncertainty on public trust in facts and numbers. (2020).
62. Bhopal, R. S. COVID-19 zugzwang: Potential public health moves towards population (herd) immunity. *Public Heal. Pract.* **1**, 100031 (2020).
63. Van Bavel, J. J. *et al.* Using social and behavioural science to support COVID-19 pandemic response. *Nat. Hum. Behav.* **4**, 460–471 (2020).

## Predictors of COVID-19 vaccine acceptance across time and countries

### Supplementary material

Table S1

Survey items and wording

Variable	Wording	Response
Gender	What is your gender?	0 =Male, 1= Female
Age	What is your age?	Age in years
Education	Please indicate your highest educational qualification	1 = No formal education above age 16, 2 = Professional or technical qualifications above age 16, 3 = School education up to age 18, 4 =Degree (Bachelors) or equivalent, 5 = Degree (Masters) or other postgraduate qualification, 6 = Doctorate [In France] 1 = No diploma, 2 =Primary school certificate, 3 = BEPC - Brevet des colleges, 4 = CAP / BEP, 5 = BAC / professional certificate / technical certificate, 6 = BAC +2 and above.
Numeracy (summed; range 1-5)	Adaptive Berlin Numeracy test (2-3items, see Cokely et al., 2012 for details). Which represents the highest risk of something happening?	Scores range 1-4 1 = '1 in 10' (correct), 2 = '1 in 1000', 3 = '1 in 100'
Politics	Where do you feel your political views lie on a spectrum of left wing (or liberal) to right wing (or conservative)?	1 = Very liberal/left, 7 = Very conservative/right
Prosociality	To what extent do you think it's important to do things for the benefit of others and society even if they have some costs to you personally?	1 = Not at all, 7 = Very much so
General social trust	Generally speaking, would you say most people can be trusted, or that you can't be too careful in dealing with people?	1 = Can't be too careful, 7 = Most people can be trusted
General trust: Experts (scale)	How much do you trust each of the following? - Medical doctors and nurses	1 = Cannot be trusted at all, 5 = Can be trusted a lot

	How much do you trust each of the following? - Scientists	1 = Cannot be trusted at all, 5 = Can be trusted a lot
	How much do you trust each of the following? - Scientific knowledge	1 = Cannot be trusted at all , 5 = Can be trusted a lot
General trust: Govt (scale)	How much do you trust each of the following? - Civil servants or public officials in the country you are living in	1 = Cannot be trusted at all , 5 = Can be trusted a lot
	How much do you trust each of the following? - The current government of the country you are living in	1 = Cannot be trusted at all , 5 = Can be trusted a lot
	How much do you trust each of the following? - Politicians in the country you are living in	1 = Cannot be trusted at all , 5 = Can be trusted a lot
COVID trust: Politicians	How much do you trust the country's politicians to deal effectively with the pandemic?	1 = Not at all, 7 = Very much
COVID Trust: National sci/med advisors	How much do you trust the country's national scientific and medical advisors to know the best measures to take in the face of the pandemic?	1 = Not at all, 7 = Very much
COVID Trust: Independent scientists	How much do you trust experts who are not connected with the government who are commenting on measures planned for the pandemic?	1 = Not at all, 7 = Very much
COVID Trust: WHO	How much do you trust the World Health Organisation to know the best measures to take in the face of the pandemic?	1 = Not at all, 7 = Very much
Personal efficacy	To what extent do you feel that the personal actions you are taking to try to limit the spread of coronavirus make a difference?	1 = Not at all, 7 = Very much
Govt efficacy	To what extent do you feel the actions that your country is taking to limit the spread of coronavirus make a difference?	1 = Not at all, 7 = Very much
Perceived infection risk (scale)	How likely do you think it is that you will be directly and personally affected by the following in the next 6 months? - Catching the coronavirus/COVID-19	1= Not at all likely, 7 = Very likely

	How likely do you think it is that your friends and family in the country you are currently living in will be directly affected by the following in the next 6 months? - Catching the coronavirus/COVID-19	1= Not at all likely, 7 = Very likely
	How much do you agree or disagree with the following statements? - I will probably get sick with the coronavirus/COVID-19.	1 = Strongly disagree, 5 = Strongly agree (rescaled)
Worry about COVID	How worried are you personally about the following issues at present? - Coronavirus/COVID-19	1 = Not at all worried, 7 = Very worried
Vaccine - acceptance	If a vaccine were to be available for the coronavirus/COVID-19 now: - Would you get vaccinated yourself?	0 = No, 1 = Yes
Vaccine – recommend to others	If a vaccine were to be available for the coronavirus/COVID-19 now: - Would you recommend vulnerable friends/family to get vaccinated?	0 = No, 1 = Yes
General vaccine attitudes	Please let us know how much you agree or disagree with the following statements about vaccines in general: - I believe that vaccines are a safe and reliable way to help avert the spread of preventable diseases	1 = Strongly disagree, 5 = Strongly agree
	Please let us know how much you agree or disagree with the following statements about vaccines in general: - Vaccinations are one of the most significant contributions to public health	1 = Strongly disagree, 5 = Strongly agree

Table S2

## Results of measurement invariance analyses

Model	Constraints	<i>Df</i>	$\chi^2$	$\Delta\chi^2$	$\Delta Df$	CFI	RMSEA	SRMR	$\Delta CFI$	$\Delta RMSEA$	$\Delta SRMR$
Trust in experts	Configural model	0	0	-	-	1	0	0	-	-	-
	Loadings	18	74.49	74.49***	18	0.998	0.039	0.017	0.002	0.039	0.017
	Intercepts	36	488.11	413.62***	18	0.981	0.079	0.035	0.017	0.039	0.018
	Means	45	983.43	495.32***	9	0.960	0.102	0.067	0.021	0.023	0.032
Trust in government	Configural model	0	0	-	-	1	0	0	-	-	-
	Loadings	18	447.63	447.63***	18	0.981	0.109	0.049	0.019	0.109	0.049
	Intercepts	36	1628.51	1180.88***	18	0.931	0.148	0.070	0.051	0.039	0.020
	Means	45	2318.57	690.06***	9	0.901	0.158	0.104	0.030	0.010	0.035
Perceived likelihood of infection	Configural model	0	0	-	-	1	0	0	-	-	-
	Loadings	18	124.79	124.79***	18	0.996	0.054	0.018	0.004	0.054	0.018
	Intercepts	36	826.98	702.19***	18	0.968	0.104	0.047	0.028	0.050	0.028
	Means	45	1036.54	209.56***	9	0.960	0.105	0.061	0.008	0.000	0.015

\*\*\* $p < .001$ , chi-square difference test

Table S3

Descriptive statistics for all samples (Mean (SD)), excluding US and UK samples (see Table S4)

	ALL	AU_D (Mar)	CN_R (Apr)	DE_R (Mar)	ES_R (Mar)	ES_R (May)	FR_B (Apr)	IT_R (Mar)	JP_R (Apr)	KR_R (Apr)	MX_R (Mar)	MX_R (May)	SE_R (Mar)	SE_R (Apr)
Age	45.27 (22.29)	46.30 (16.44)	43.21 (14.26)	46.61 (16.00)	46.64 (15.03)	46.00 (15.03)	48.79 (16.53)	46.95 (26.06)	48.08 (16.35)	45.34 (15.51)	38.39 (14.24)	38.68 (14.56)	48.41 (77.28)	45.31 (16.74)
Gender (Female)	0.51 (0.50)	0.51 (0.50)	0.49 (0.50)	0.50 (0.50)	0.51 (0.50)	0.50 (0.50)	0.48 (0.50)	0.50 (0.50)	0.51 (0.50)	0.49 (0.50)	0.50 (0.50)	0.51 (0.50)	0.49 (0.50)	0.49 (0.50)
Education	3.42 (1.13)	3.17 (1.12)	3.64 (0.88)	3.07 (1.19)	3.59 (1.08)	3.60 (1.07)	5.00 <sup>a</sup> (1.12)	3.51 (1.23)	3.56 (0.81)	3.76 (0.79)	3.55 (0.94)	3.74 (0.88)	3.30 (1.06)	3.34 (1.01)
Numeracy	2.66 (1.11)	2.41 (1.06)	2.83 (1.25)	2.53 (1.12)	2.39 (1.03)	2.42 (0.97)	2.18 (0.70)	2.13 (0.71)	2.77 (1.25)	2.60 (1.06)	2.16 (0.90)	2.31 (0.95)	2.52 (1.23)	2.57 (1.21)
Politics (Conservative)	3.74 (1.41)	3.83 (1.30)	-	3.79 (1.19)	3.50 (1.43)	3.44 (1.50)	-	3.87 (1.45)	4.09 (1.09)	3.88 (1.20)	3.65 (1.31)	3.57 (1.33)	3.92 (1.59)	3.88 (1.61)
Prosociality	5.21 (1.36)	5.23 (1.36)	5.54 (1.19)	4.97 (1.42)	5.74 (1.21)	5.35 (1.34)	5.23 (1.41)	5.76 (1.38)	4.74 (1.42)	4.40 (1.31)	5.34 (1.61)	5.26 (1.53)	4.87 (1.43)	4.63 (1.48)
General social trust	3.66 (1.71)	3.95 (1.67)	4.96 (1.67)	3.61 (1.65)	3.47 (1.87)	3.29 (1.77)	2.98 (1.62)	3.70 (1.61)	3.85 (1.48)	3.97 (1.50)	2.81 (1.84)	2.94 (1.84)	3.73 (1.73)	3.85 (1.73)
General trust: Experts	3.97 (0.77)	3.97 (0.79)	4.26 (0.61)	3.90 (0.74)	4.19 (0.72)	4.09 (0.76)	3.76 (0.81)	4.02 (0.74)	3.51 (0.72)	3.74 (0.68)	4.05 (0.85)	4.10 (0.83)	3.90 (0.75)	3.85 (0.75)
General trust: Govt	2.64 (0.91)	2.96 (0.93)	-	3.14 (0.92)	2.75 (0.94)	2.54 (0.89)	2.48 (0.90)	2.89 (0.91)	2.46 (0.84)	2.65 (0.81)	2.28 (1.01)	2.35 (1.02)	3.04 (1.00)	3.00 (1.01)
COVID trust: Politicians	3.48 (1.87)	4.44 (1.75)	-	4.80 (1.65)	4.01 (1.88)	3.45 (1.91)	3.33 (1.78)	4.35 (1.74)	3.03 (1.60)	4.24 (1.63)	3.22 (1.99)	3.51 (1.96)	4.13 (1.78)	4.24 (1.83)
COVID Trust: National sci/med advisors	4.91 (1.60)	5.34 (1.41)	-	5.40 (1.43)	5.45 (1.39)	4.92 (1.65)	4.46 (1.73)	5.42 (1.40)	3.90 (1.51)	5.15 (1.37)	5.18 (1.69)	5.28 (1.60)	4.78 (1.67)	4.93 (1.66)
COVID Trust: Independent scientists	4.66 (1.55)	4.77 (1.49)	-	5.11 (1.38)	5.15 (1.39)	4.83 (1.55)	4.62 (1.52)	4.80 (1.45)	3.73 (1.51)	5.03 (1.26)	5.02 (1.68)	4.91 (1.65)	4.66 (1.52)	4.55 (1.48)
COVID Trust: WHO	4.84 (1.68)	5.19 (1.55)	-	5.16 (1.52)	5.46 (1.42)	4.88 (1.62)	4.80 (1.61)	5.25 (1.48)	3.12 (1.55)	3.96 (1.51)	5.80 (1.45)	5.58 (1.62)	5.05 (1.45)	4.81 (1.55)
Personal efficacy	5.22 (1.48)	5.14 (1.45)	-	5.24 (1.41)	5.31 (1.47)	5.14 (1.47)	5.20 (1.47)	5.31 (1.46)	4.26 (1.42)	5.42 (1.24)	5.36 (1.66)	5.56 (1.53)	5.20 (1.50)	5.26 (1.45)
Govt efficacy	3.86 (1.78)	4.48 (1.63)	-	4.68 (1.47)	4.21 (1.77)	4.11 (1.83)	4.22 (1.68)	4.60 (1.60)	3.21 (1.52)	5.08 (1.52)	3.82 (2.06)	4.39 (1.86)	4.30 (1.73)	4.41 (1.67)
Perceived infection risk	4.17 (1.32)	4.16 (1.40)	3.26 (1.37)	4.13 (1.34)	4.46 (1.23)	4.38 (1.26)	4.19 (1.24)	3.93 (1.30)	4.48 (1.20)	4.37 (1.22)	4.16 (1.47)	4.29 (1.43)	4.30 (1.37)	4.37 (1.29)
Worry about COVID	5.56 (1.52)	5.56 (1.51)	5.37 (1.57)	5.66 (1.49)	6.25 (1.17)	6.11 (1.26)	5.63 (1.43)	6.08 (1.27)	5.83 (1.28)	5.59 (1.29)	5.92 (1.46)	6.06 (1.35)	5.27 (1.55)	4.98 (1.66)
Vaccine – acceptance	0.76 (0.43)	0.83 (0.38)	0.86 (0.35)	0.81 (0.39)	0.84 (0.37)	0.80 (0.40)	0.70 (0.46)	0.85 (0.35)	0.74 (0.44)	0.86 (0.35)	0.88 (0.32)	0.74 (0.44)	0.66 (0.47)	0.63 (0.48)
Vaccine – recommend to vulnerable others	0.82 (0.38)	0.89 (0.32)	0.87 (0.33)	0.89 (0.31)	0.90 (0.30)	0.82 (0.38)	0.81 (0.40)	0.88 (0.32)	0.80 (0.40)	0.88 (0.32)	0.90 (0.30)	0.76 (0.43)	0.77 (0.42)	0.74 (0.44)
General vaccine attitudes	4.05 (1.11)	-	-	-	-	-	-	-	-	-	-	-	-	-

<sup>a</sup> Education item in France differed from other surveys – see Table S1.

Table S4

Descriptive statistics for all US and UK samples (Mean (SD))

	UK_P (Mar)	UK_P (May)	UK_P (Jul)	UK_P (Sep)	UK_R (May)	UK_R (Jun)	UK_R (Jul)	UK_R (Sep)	UK_R (Oct)	US_P (Mar)	US_R (May)	US_R (Sep)
Age	45.63 (15.69)	45.22 (23.08)	44.76 (17.55)	38.14 (15.01)	45.64 (15.99)	45.90 (15.87)	46.01 (24.36)	45.75 (19.58)	47.13 (23.44)	45.09 (15.90)	45.73 (26.53)	44.76 (15.60)
Gender (Female)	0.51 (0.50)	0.51 (0.50)	0.53 (0.50)	0.52 (0.50)	0.52 (0.50)	0.53 (0.50)	0.52 (0.50)	0.52 (0.50)	0.52 (0.50)	0.51 (0.50)	0.51 (0.50)	0.51 (0.50)
Education	3.45 (1.17)	3.50 (1.14)	3.58 (1.14)	3.54 (1.10)	3.17 (1.27)	-	3.20 (1.23)	3.15 (1.28)	3.10 (1.23)	3.87 (0.88)	3.70 (0.90)	-
Numeracy	3.22 (1.17)	3.23 (1.14)	3.04 (1.06)	3.24 (1.15)	2.64 (1.14)	2.74 (1.10)	2.61 (1.07)	2.60 (1.07)	2.78 (1.11)	3.14 (1.13)	2.76 (1.14)	2.58 (1.12)
Politics (Conservative)	3.69 (1.43)	3.67 (1.39)	3.58 (1.36)	3.37 (1.36)	3.90 (1.35)	3.89 (1.19)	3.90 (1.33)	3.84 (1.36)	3.83 (1.32)	3.22 (1.65)	3.92 (1.69)	4.07 (1.65)
Prosociality	5.50 (1.07)	5.36 (1.19)	5.32 (1.16)	5.42 (1.17)	5.12 (1.33)	5.25 (1.29)	5.03 (1.29)	5.08 (1.39)	5.38 (1.36)	5.43 (1.28)	5.05 (1.36)	5.02 (1.44)
General social trust	4.04 (1.59)	4.12 (1.55)	4.11 (1.55)	3.69 (1.56)	3.74 (1.71)	3.58 (1.70)	3.86 (1.59)	3.68 (1.68)	3.66 (1.64)	4.01 (1.68)	3.79 (1.73)	3.47 (1.84)
General trust: Experts	4.24 (0.66)	4.11 (0.63)	4.14 (0.66)	4.17 (0.68)	3.89 (0.79)	3.88 (0.81)	3.92 (0.76)	3.90 (0.78)	3.92 (0.77)	4.22 (0.73)	3.96 (0.77)	3.89 (0.83)
General trust: Govt	2.82 (0.85)	2.80 (0.82)	2.60 (0.82)	2.44 (0.81)	2.82 (0.87)	2.64 (0.87)	2.70 (0.88)	2.60 (0.90)	2.55 (0.86)	2.55 (0.79)	2.68 (0.83)	2.52 (0.88)
COVID trust: Politicians	3.81 (1.78)	3.80 (1.81)	3.16 (1.80)	2.57 (1.65)	4.00 (1.86)	3.38 (1.70)	3.60 (1.83)	3.23 (1.86)	3.04 (1.79)	3.06 (1.74)	3.11 (1.77)	2.93 (1.81)
COVID Trust: National sci/med advisors	5.27 (1.47)	5.13 (1.41)	5.12 (1.47)	4.88 (1.58)	4.94 (1.57)	4.58 (1.51)	4.88 (1.53)	4.66 (1.61)	4.60 (1.66)	5.46 (1.41)	5.15 (1.55)	-
COVID Trust: Independent scientists	4.88 (1.48)	4.59 (1.44)	4.74 (1.48)	4.77 (1.60)	4.46 (1.52)	-	4.54 (1.52)	4.40 (1.61)	4.28 (1.63)	5.16 (1.48)	4.72 (1.60)	-
COVID Trust: WHO	5.59 (1.40)	4.97 (1.55)	5.02 (1.62)	4.77 (1.70)	4.76 (1.69)	4.46 (1.69)	4.72 (1.66)	4.50 (1.69)	4.44 (1.71)	5.62 (1.55)	4.57 (1.90)	-
Personal efficacy	5.04 (1.39)	5.59 (1.26)	5.47 (1.35)	5.12 (1.48)	5.36 (1.48)	5.13 (1.45)	5.30 (1.45)	5.09 (1.52)	5.03 (1.52)	5.25 (1.45)	5.32 (1.47)	5.14 (1.57)
Govt efficacy	3.86 (1.75)	3.85 (1.70)	3.48 (1.72)	3.03 (1.62)	4.13 (1.74)	3.66 (1.61)	3.88 (1.75)	3.58 (1.73)	3.36 (1.70)	3.28 (1.80)	3.76 (1.76)	3.25 (1.86)
Perceived infection risk	4.89 (1.32)	4.26 (1.24)	3.96 (1.24)	4.26 (1.30)	4.14 (1.22)	3.94 (1.25)	3.86 (1.25)	4.13 (1.28)	4.27 (1.24)	3.98 (1.52)	3.91 (1.38)	4.11 (1.38)
Worry about COVID	5.80 (1.36)	5.72 (1.40)	5.28 (1.52)	5.36 (1.58)	5.60 (1.51)	5.34 (1.57)	5.30 (1.60)	5.39 (1.61)	5.39 (1.63)	5.49 (1.58)	5.58 (1.60)	5.43 (1.72)
Vaccine – acceptance	0.80 (0.40)	0.80 (0.40)	0.79 (0.41)	0.73 (0.44)	0.79 (0.41)	0.79 (0.41)	0.80 (0.40)	0.76 (0.43)	0.72 (0.45)	0.76 (0.43)	0.75 (0.44)	0.63 (0.48)
Vaccine – recommend to vulnerable others	0.92 (0.28)	0.87 (0.34)	0.85 (0.36)	0.80 (0.40)	0.84 (0.36)	0.83 (0.38)	0.84 (0.36)	0.80 (0.40)	0.76 (0.43)	0.86 (0.35)	0.80 (0.40)	0.68 (0.47)
General vaccine attitudes	-	-	-	4.21 (1.10)	-	-	-	3.90 (1.14)	4.05 (1.06)	-	-	-



Table S5

Full logistic regression results from model predicting vaccine acceptance, excluding UK and US samples (shown in Table S6)

	ALL OR	ALL (-UK) OR	AU_D (Mar) OR	DE_R (Mar) OR	ES_R (Mar) OR	ES_R (May) OR	IT_R (Mar) OR	JP_R (Apr) OR	KR_R (Apr) OR	MX_R (Mar) OR	MX_R (May) OR	SE_R (Mar) OR	SE_R (Apr) OR
(Intercept)	5.23 *** [4.94 – 5.54]	5.22 *** [4.79 – 5.69]	5.59 *** [4.08 – 7.83]	9.38 *** [6.51 – 13.96]	8.10 *** [5.74 – 11.79]	7.35 *** [5.28 – 10.50]	11.73 *** [7.54 – 19.18]	3.70 *** [2.78 – 4.99]	7.89 *** [5.66 – 11.31]	15.24 *** [9.74 – 25.20]	5.43 *** [3.99 – 7.55]	3.17 *** [2.45 – 4.14]	2.20 *** [1.71 – 2.86]
Age	1.16 *** [1.10 – 1.23]	1.00 [0.95 – 1.07]	1.12 [0.88 – 1.42]	1.61 *** [1.27 – 2.06]	1.10 [0.87 – 1.38]	1.00 [0.80 – 1.25]	1.15 [0.79 – 1.91]	1.23 [1.00 – 1.52]	0.97 [0.77 – 1.23]	0.73 * [0.55 – 0.96]	0.86 [0.70 – 1.05]	0.92 [0.56 – 1.09]	1.47 *** [1.21 – 1.79]
Gender (Female) <sup>a</sup>	0.59 *** [0.55 – 0.64]	0.61 *** [0.55 – 0.69]	1.20 [0.76 – 1.88]	0.37 *** [0.23 – 0.59]	0.53 ** [0.33 – 0.83]	0.47 *** [0.30 – 0.72]	0.59 [0.34 – 1.03]	0.76 [0.50 – 1.13]	0.75 [0.48 – 1.19]	0.49 * [0.27 – 0.87]	0.42 *** [0.28 – 0.62]	0.43 *** [0.30 – 0.62]	0.71 [0.49 – 1.03]
Education	1.02 [0.98 – 1.06]	1.00 [0.94 – 1.05]	0.85 [0.67 – 1.07]	0.86 [0.68 – 1.08]	0.95 [0.77 – 1.18]	1.11 [0.90 – 1.36]	0.98 [0.74 – 1.30]	1.13 [0.93 – 1.39]	0.98 [0.78 – 1.23]	0.94 [0.70 – 1.25]	0.99 [0.81 – 1.20]	1.03 [0.86 – 1.23]	0.97 [0.81 – 1.16]
Numeracy	1.01 [0.97 – 1.05]	0.93 * [0.88 – 0.99]	0.91 [0.73 – 1.15]	0.84 [0.67 – 1.05]	0.80 * [0.65 – 0.99]	0.88 [0.72 – 1.09]	0.64 ** [0.48 – 0.84]	0.99 [0.81 – 1.23]	0.92 [0.73 – 1.16]	0.95 [0.73 – 1.25]	1.00 [0.82 – 1.22]	0.92 [0.77 – 1.11]	1.01 [0.84 – 1.22]
Politics (Conservative)	0.94 ** [0.90 – 0.98]	0.95 [0.90 – 1.00]	0.87 [0.68 – 1.11]	1.21 [0.96 – 1.52]	1.23 [0.98 – 1.55]	1.06 [0.84 – 1.33]	0.88 [0.66 – 1.18]	1.02 [0.84 – 1.25]	1.02 [0.80 – 1.30]	0.86 [0.65 – 1.14]	1.18 [0.97 – 1.44]	0.91 [0.76 – 1.10]	0.91 [0.75 – 1.10]
Prosociality	1.07 ** [1.03 – 1.11]	1.06 * [1.00 – 1.13]	0.98 [0.75 – 1.26]	1.05 [0.82 – 1.35]	0.98 [0.78 – 1.24]	1.20 [0.96 – 1.50]	1.05 [0.78 – 1.39]	1.16 [0.93 – 1.45]	1.26 [0.98 – 1.62]	1.01 [0.76 – 1.32]	0.99 [0.81 – 1.22]	0.96 [0.79 – 1.16]	0.96 [0.79 – 1.16]
General social trust	1.06 ** [1.02 – 1.11]	1.06 [1.00 – 1.13]	1.18 [0.91 – 1.52]	0.96 [0.75 – 1.24]	0.93 [0.73 – 1.17]	1.15 [0.92 – 1.44]	0.99 [0.74 – 1.33]	0.97 [0.77 – 1.22]	1.14 [0.87 – 1.48]	1.25 [0.94 – 1.70]	0.93 [0.76 – 1.14]	0.99 [0.81 – 1.20]	1.01 [0.83 – 1.23]
General trust: Experts	1.27 *** [1.22 – 1.33]	1.26 *** [1.18 – 1.35]	1.38 * [1.06 – 1.80]	0.90 [0.66 – 1.21]	1.33 * [1.02 – 1.73]	1.55 *** [1.23 – 1.97]	1.45 * [1.05 – 2.01]	1.25 [0.97 – 1.60]	1.30 [1.00 – 1.71]	1.05 [0.77 – 1.40]	1.46 ** [1.16 – 1.84]	1.15 [0.91 – 1.44]	1.19 [0.95 – 1.49]
General trust: Govt	1.02 [0.96 – 1.07]	0.93 [0.86 – 1.01]	0.74 [0.54 – 1.00]	1.06 [0.77 – 1.47]	1.24 [0.91 – 1.70]	1.01 [0.76 – 1.34]	0.97 [0.67 – 1.39]	1.07 [0.81 – 1.40]	0.70 * [0.52 – 0.93]	1.29 [0.90 – 1.89]	1.01 [0.78 – 1.31]	0.97 [0.75 – 1.26]	1.06 [0.79 – 1.42]
COVID trust: Politicians	1.06 [1.00 – 1.13]	1.04 [0.94 – 1.13]	1.14 [0.78 – 1.66]	1.49 * [1.02 – 2.20]	1.16 [0.83 – 1.63]	1.13 [0.81 – 1.57]	0.72 [0.45 – 1.12]	0.98 [0.67 – 1.41]	1.17 [0.86 – 1.58]	0.91 [0.61 – 1.36]	1.09 [0.80 – 1.47]	1.16 [0.85 – 1.59]	0.89 [0.64 – 1.23]
COVID Trust: National sci/med advisors	1.22 *** [1.15 – 1.28]	1.22 *** [1.12 – 1.32]	1.08 [0.76 – 1.52]	0.95 [0.64 – 1.42]	0.95 [0.69 – 1.31]	1.66 *** [1.24 – 2.24]	1.13 [0.72 – 1.78]	1.08 [0.79 – 1.48]	0.88 [0.63 – 1.24]	1.23 [0.89 – 1.70]	1.08 [0.82 – 1.42]	1.05 [0.79 – 1.41]	1.04 [0.77 – 1.41]
COVID Trust: Independent scientists	0.95 * [0.90 – 0.99]	1.00 [0.93 – 1.07]	1.02 [0.76 – 1.34]	0.88 [0.64 – 1.21]	1.00 [0.76 – 1.31]	0.73 * [0.56 – 0.95]	0.99 [0.70 – 1.37]	1.05 [0.78 – 1.41]	1.01 [0.74 – 1.37]	1.05 [0.78 – 1.42]	1.12 [0.89 – 1.41]	0.99 [0.78 – 1.24]	1.03 [0.83 – 1.27]
COVID Trust: WHO	1.19 *** [1.13 – 1.24]	1.10 ** [1.03 – 1.18]	0.96 [0.71 – 1.28]	1.57 ** [1.15 – 2.14]	1.00 [0.74 – 1.33]	1.03 [0.78 – 1.35]	1.11 [0.74 – 1.63]	0.90 [0.69 – 1.18]	1.07 [0.83 – 1.38]	1.12 [0.82 – 1.53]	1.59 *** [1.24 – 2.04]	1.15 [0.91 – 1.45]	1.28 * [1.02 – 1.60]
Personal efficacy	1.01 [0.97 – 1.06]	0.93 * [0.87 – 0.99]	0.85 [0.64 – 1.12]	1.05 [0.81 – 1.35]	0.93 [0.71 – 1.21]	0.91 [0.71 – 1.16]	1.02 [0.73 – 1.43]	0.92 [0.72 – 1.18]	1.01 [0.75 – 1.36]	0.86 [0.62 – 1.17]	0.82 [0.64 – 1.05]	0.74 ** [0.60 – 0.92]	1.09 [0.90 – 1.33]
Govt efficacy	1.01 [0.96 – 1.07]	1.07 [0.98 – 1.16]	1.25 [0.88 – 1.79]	0.94 [0.70 – 1.26]	0.97 [0.70 – 1.33]	1.08 [0.79 – 1.47]	1.35 [0.92 – 1.98]	1.15 [0.81 – 1.64]	1.05 [0.75 – 1.46]	1.00 [0.68 – 1.50]	0.89 [0.66 – 1.19]	1.20 [0.89 – 1.61]	1.13 [0.85 – 1.50]
Perceived infection risk	1.12 *** [1.07 – 1.16]	1.13 *** [1.07 – 1.20]	1.06 [0.82 – 1.37]	1.49 ** [1.16 – 1.92]	1.00 [0.80 – 1.25]	1.11 [0.89 – 1.38]	1.47 ** [1.11 – 1.96]	1.20 [0.97 – 1.48]	1.07 [0.83 – 1.38]	1.43 * [1.06 – 1.92]	1.27 * [1.02 – 1.57]	1.30 ** [1.07 – 1.58]	0.79 * [0.65 – 0.97]
Worry about COVID	1.49 *** [1.43 – 1.55]	1.53 *** [1.44 – 1.62]	1.69 *** [1.34 – 2.16]	1.34 * [1.05 – 1.70]	1.37 * [1.07 – 1.74]	1.19 [0.95 – 1.48]	1.55 ** [1.18 – 2.03]	1.33 ** [1.07 – 1.65]	1.24 [0.96 – 1.59]	1.66 *** [1.26 – 2.21]	1.31 * [1.06 – 1.63]	1.37 ** [1.13 – 1.66]	1.77 *** [1.44 – 2.19]
Observations	19256	8418	644	641	669	666	532	590	677	629	684	653	656
R <sup>2</sup> Tjur	0.126	0.102	0.096	0.183	0.061	0.137	0.142	0.077	0.04	0.115	0.196	0.102	0.137

Odd ratios [95CI] shown, all continuous measure were standardized (scaled and mean-centered) prior to analysis. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific). <sup>a</sup>Gender is unstandardized

\*p < .05, \*\*p < .01, \*\*\* p < .001

Table S6

Full logistic regression results from model predicting vaccine acceptance, UK and US samples

	UK_P (Mar)	UK_P (May)	UK_P (Jul)	UK_P (Sep)	UK_R (May)	UK_R (Jul)	UK_R (Sep)	UK_R (Oct)	US_P (Mar)	US_R (May)
	OR	OR	OR	OR	OR	OR	OR	OR	OR	OR
(Intercept)	5.20 ***	7.66 ***	6.20 ***	4.16 ***	5.62 ***	6.52 ***	5.55 ***	4.94 ***	4.66 ***	5.11 ***
	[3.87 – 7.11]	[5.86 – 10.18]	[4.91 – 7.93]	[3.48 – 4.99]	[4.38 – 7.33]	[5.11 – 8.43]	[4.56 – 6.79]	[4.07 – 6.03]	[3.46 – 6.38]	[3.71 – 7.21]
Age	1.18	1.60 ***	1.06	1.12	1.48 ***	1.12	1.48 ***	1.60 ***	0.91	1.40
	[0.96 – 1.46]	[1.23 – 2.10]	[0.90 – 1.28]	[0.99 – 1.28]	[1.22 – 1.79]	[0.95 – 1.41]	[1.26 – 1.75]	[1.31 – 1.95]	[0.74 – 1.12]	[0.96 – 2.07]
Gender (Female)	0.79	0.53 ***	0.58 ***	0.61 ***	0.78	0.67 *	0.50 ***	0.44 ***	0.72	0.75
	[0.52 – 1.20]	[0.37 – 0.75]	[0.43 – 0.79]	[0.48 – 0.78]	[0.56 – 1.09]	[0.48 – 0.93]	[0.39 – 0.65]	[0.34 – 0.57]	[0.48 – 1.09]	[0.49 – 1.15]
Education	0.98	0.85	1.10	1.02	1.04	1.00	1.11	1.18 *	1.08	1.06
	[0.80 – 1.21]	[0.71 – 1.00]	[0.95 – 1.29]	[0.91 – 1.15]	[0.88 – 1.24]	[0.85 – 1.18]	[0.98 – 1.26]	[1.04 – 1.34]	[0.88 – 1.32]	[0.86 – 1.31]
Numeracy	1.30 *	0.99	1.19 *	1.11	1.25 *	1.10	1.00	1.00	1.21	1.42 **
	[1.05 – 1.62]	[0.84 – 1.17]	[1.01 – 1.39]	[0.98 – 1.26]	[1.05 – 1.48]	[0.93 – 1.29]	[0.88 – 1.14]	[0.88 – 1.13]	[0.98 – 1.50]	[1.14 – 1.79]
Politics (Conservative)	0.83	0.90	0.94	0.84 *	0.91	0.99	0.88	0.86 *	0.73 *	0.75 *
	[0.66 – 1.05]	[0.74 – 1.09]	[0.79 – 1.13]	[0.74 – 0.97]	[0.76 – 1.10]	[0.83 – 1.19]	[0.77 – 1.01]	[0.74 – 0.98]	[0.57 – 0.93]	[0.57 – 0.99]
Prosociality	1.09	1.19 *	1.16 *	1.11	0.89	1.05	1.09	1.07	1.00	1.19
	[0.89 – 1.34]	[1.01 – 1.41]	[1.00 – 1.35]	[0.98 – 1.26]	[0.74 – 1.06]	[0.89 – 1.24]	[0.96 – 1.25]	[0.94 – 1.23]	[0.81 – 1.23]	[0.94 – 1.49]
General social trust	0.85	1.04	0.98	1.03	1.06	1.24 *	1.09	0.97	1.14	0.98
	[0.68 – 1.06]	[0.86 – 1.25]	[0.83 – 1.17]	[0.91 – 1.16]	[0.88 – 1.27]	[1.04 – 1.48]	[0.95 – 1.25]	[0.85 – 1.11]	[0.91 – 1.44]	[0.78 – 1.24]
General trust: Experts	1.06	1.39 **	1.34 ***	1.39 ***	1.12	1.44 ***	1.24 **	1.45 ***	1.53 **	1.38 *
	[0.83 – 1.34]	[1.13 – 1.70]	[1.13 – 1.60]	[1.21 – 1.61]	[0.91 – 1.38]	[1.19 – 1.73]	[1.06 – 1.44]	[1.24 – 1.69]	[1.16 – 2.03]	[1.03 – 1.84]
General trust:Govt	1.27	1.00	1.07	1.27 **	1.13	1.07	1.13	1.02	0.87	0.95
	[0.96 – 1.68]	[0.79 – 1.27]	[0.86 – 1.32]	[1.07 – 1.50]	[0.90 – 1.42]	[0.85 – 1.33]	[0.94 – 1.36]	[0.86 – 1.21]	[0.67 – 1.14]	[0.71 – 1.26]
COVID trust: Politicians	1.17	0.98	1.09	0.94	1.00	1.22	1.12	1.26 *	1.21	1.03
	[0.82 – 1.67]	[0.73 – 1.31]	[0.84 – 1.42]	[0.77 – 1.14]	[0.76 – 1.33]	[0.90 – 1.65]	[0.90 – 1.41]	[1.02 – 1.57]	[0.86 – 1.69]	[0.74 – 1.42]
COVID Trust: National sci/med advisors	1.18	1.50 ***	1.23 *	1.13	1.17	0.98	1.25 *	1.29 **	0.78	1.92 ***
	[0.88 – 1.59]	[1.18 – 1.89]	[1.00 – 1.51]	[0.97 – 1.33]	[0.92 – 1.49]	[0.77 – 1.25]	[1.04 – 1.50]	[1.07 – 1.56]	[0.57 – 1.04]	[1.39 – 2.69]
COVID Trust: Independent scientists	1.08	0.89	0.82 *	0.93	0.85	1.00	0.88	1.00	1.12	0.81
	[0.84 – 1.37]	[0.73 – 1.08]	[0.68 – 0.98]	[0.80 – 1.07]	[0.68 – 1.05]	[0.81 – 1.22]	[0.74 – 1.03]	[0.85 – 1.17]	[0.89 – 1.41]	[0.62 – 1.06]
COVID Trust: WHO	1.05	1.26 *	1.23 *	1.45 ***	1.52 ***	1.04	1.33 ***	1.03	1.17	1.02
	[0.80 – 1.35]	[1.04 – 1.53]	[1.02 – 1.49]	[1.25 – 1.69]	[1.23 – 1.88]	[0.83 – 1.29]	[1.12 – 1.58]	[0.87 – 1.23]	[0.90 – 1.51]	[0.76 – 1.37]
Personal efficacy	1.06	1.10	1.07	1.10	1.06	1.21 *	1.03	1.03	1.23	1.08
	[0.86 – 1.31]	[0.92 – 1.30]	[0.91 – 1.25]	[0.96 – 1.25]	[0.87 – 1.29]	[1.01 – 1.45]	[0.89 – 1.19]	[0.89 – 1.18]	[0.99 – 1.52]	[0.84 – 1.39]
Govt efficacy	0.84	0.82	1.05	1.01	1.02	0.94	0.95	1.04	1.05	0.97
	[0.62 – 1.13]	[0.63 – 1.05]	[0.83 – 1.33]	[0.84 – 1.21]	[0.80 – 1.31]	[0.72 – 1.24]	[0.77 – 1.16]	[0.86 – 1.27]	[0.77 – 1.43]	[0.71 – 1.33]
Perceived infection risk	1.18	1.39 ***	1.30 **	1.04	1.19	1.15	1.08	0.98	1.26	1.45 **
	[0.96 – 1.46]	[1.16 – 1.66]	[1.09 – 1.54]	[0.91 – 1.19]	[0.99 – 1.42]	[0.96 – 1.38]	[0.94 – 1.25]	[0.85 – 1.13]	[1.00 – 1.59]	[1.14 – 1.86]
Worry about COVID-19	1.10	1.25 *	1.40 ***	1.36 ***	1.59 ***	1.62 ***	1.56 ***	1.44 ***	1.48 **	1.27
	[0.88 – 1.36]	[1.04 – 1.48]	[1.18 – 1.65]	[1.19 – 1.57]	[1.34 – 1.89]	[1.35 – 1.95]	[1.35 – 1.80]	[1.24 – 1.66]	[1.17 – 1.87]	[0.99 – 1.64]
Observations	698	1144	1315	1847	1098	1254	1778	1704	694	683
R <sup>2</sup> Tjur	0.068	0.172	0.161	0.191	0.168	0.16	0.173	0.193	0.184	0.287

Odd ratios [95CI] shown, all continuous measure were standardized (scaled and mean-centered) prior to analysis. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific). <sup>a</sup>Gender is unstandardized

\*p < .05, \*\*p < .01, \*\*\* p < .001




Figure S1. Point biserial correlations between predictors and vaccine acceptance across all samples. Greyed values are non-significant ( $p > .05$ ). Blank spaces indicate predictors which were not included in a given survey.




Figure S2. Heatmap of odds ratios in model predicting recommending vaccine to vulnerable friends/family. Columns represent individual samples and rows represent predictors in model. Grey values are non-significant,  $p > .05$ . Red shading indicates a lower likelihood of vaccine acceptance and blue shading a higher likelihood. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific).

Table S7

Full logistic regression results from model predicting vaccine recommendation to vulnerable others, excluding UK and US samples (shown in Table S8)

	ALL OR	AU_D (Mar) OR	DE_R (Mar) OR	ES_R (Mar) OR	ES_R (May) OR	IT_R (Mar) OR	JP_R (Apr) OR	KR_R (Apr) OR	MX_R (Mar) OR	MX_R (May) OR	SE_R (Mar) OR	SE_R (Apr) OR
(Intercept)	7.74 *** [7.25 – 8.27]	10.40 *** [7.01 – 16.08]	21.17 *** [13.08 – 36.39]	13.42 *** [8.85 – 21.37]	8.84 *** [6.21 – 12.98]	14.20 *** [8.89 – 24.03]	4.88 *** [3.58 – 6.79]	11.66 *** [7.94 – 17.84]	22.92 *** [13.58 – 41.94]	5.11 *** [3.78 – 7.06]	5.38 *** [3.99 – 7.42]	3.60 *** [2.73 – 4.83]
Age	1.16 *** [1.09 – 1.24]	1.40 * [1.05 – 1.88]	1.47 * [1.08 – 2.00]	1.06 [0.80 – 1.40]	1.04 [0.83 – 1.32]	1.03 [0.77 – 1.70]	1.03 [0.81 – 1.29]	1.12 [0.86 – 1.48]	0.79 [0.58 – 1.07]	0.82 [0.67 – 1.01]	0.90 [0.63 – 1.07]	1.43 ** [1.15 – 1.78]
Gender (Female) <sup>a</sup>	0.65 *** [0.60 – 0.71]	1.22 [0.71 – 2.10]	0.45 ** [0.25 – 0.80]	0.70 [0.39 – 1.21]	0.52 ** [0.32 – 0.81]	0.71 [0.38 – 1.29]	0.96 [0.62 – 1.50]	0.79 [0.47 – 1.32]	0.40 ** [0.20 – 0.77]	0.54 ** [0.36 – 0.80]	0.53 ** [0.35 – 0.81]	0.79 [0.53 – 1.18]
Education	1.01 [0.97 – 1.06]	0.93 [0.70 – 1.23]	0.70 * [0.52 – 0.92]	0.99 [0.76 – 1.28]	0.95 [0.76 – 1.18]	0.94 [0.69 – 1.28]	1.24 [0.99 – 1.55]	0.78 [0.59 – 1.02]	0.91 [0.65 – 1.24]	0.99 [0.82 – 1.21]	0.78 * [0.64 – 0.96]	1.12 [0.92 – 1.36]
Numeracy	1.08 *** [1.03 – 1.12]	1.04 [0.79 – 1.40]	1.17 [0.88 – 1.58]	0.97 [0.75 – 1.27]	0.95 [0.76 – 1.19]	0.89 [0.65 – 1.23]	0.87 [0.70 – 1.10]	1.10 [0.84 – 1.45]	0.92 [0.68 – 1.25]	1.05 [0.85 – 1.29]	1.07 [0.87 – 1.33]	1.05 [0.86 – 1.28]
Politics (Conservative)	0.98 [0.94 – 1.02]	0.81 [0.60 – 1.08]	0.98 [0.73 – 1.31]	0.97 [0.74 – 1.29]	0.98 [0.77 – 1.24]	1.31 [0.96 – 1.78]	1.07 [0.86 – 1.33]	0.89 [0.67 – 1.17]	0.88 [0.64 – 1.21]	1.09 [0.89 – 1.33]	1.08 [0.88 – 1.33]	0.97 [0.79 – 1.19]
Prosociality	1.08 *** [1.03 – 1.13]	0.96 [0.70 – 1.31]	1.57 ** [1.14 – 2.17]	1.14 [0.87 – 1.49]	1.18 [0.94 – 1.49]	1.25 [0.93 – 1.67]	1.61 *** [1.26 – 2.07]	1.26 [0.95 – 1.66]	0.97 [0.72 – 1.31]	1.05 [0.86 – 1.29]	1.07 [0.86 – 1.31]	1.07 [0.88 – 1.32]
General social trust	1.06 ** [1.01 – 1.11]	0.87 [0.62 – 1.19]	0.66 * [0.47 – 0.92]	0.97 [0.72 – 1.31]	1.11 [0.87 – 1.41]	1.05 [0.76 – 1.44]	0.82 [0.63 – 1.07]	1.05 [0.78 – 1.42]	1.19 [0.87 – 1.67]	0.99 [0.81 – 1.22]	0.99 [0.79 – 1.24]	1.00 [0.81 – 1.24]
General trust: Experts	1.36 *** [1.30 – 1.43]	1.21 [0.89 – 1.63]	1.25 [0.85 – 1.83]	1.27 [0.92 – 1.74]	1.53 *** [1.20 – 1.96]	1.56 ** [1.12 – 2.19]	1.28 [0.97 – 1.69]	1.51 ** [1.12 – 2.05]	1.16 [0.84 – 1.59]	1.44 ** [1.15 – 1.82]	1.44 ** [1.12 – 1.85]	1.28 * [1.01 – 1.61]
General trust: Govt	1.01 [0.95 – 1.07]	1.03 [0.72 – 1.47]	0.71 [0.46 – 1.10]	1.76 ** [1.20 – 2.62]	0.96 [0.71 – 1.30]	1.16 [0.78 – 1.72]	0.88 [0.66 – 1.18]	0.56 *** [0.40 – 0.77]	1.29 [0.86 – 1.97]	0.91 [0.70 – 1.18]	0.97 [0.72 – 1.30]	1.06 [0.77 – 1.45]
COVID trust: Politicians	1.09 * [1.01 – 1.17]	0.94 [0.59 – 1.49]	1.23 [0.75 – 2.02]	0.57 * [0.36 – 0.89]	1.32 [0.93 – 1.90]	0.89 [0.55 – 1.44]	1.13 [0.75 – 1.72]	1.27 [0.89 – 1.82]	0.94 [0.60 – 1.47]	1.14 [0.83 – 1.55]	1.56 * [1.10 – 2.22]	0.78 [0.54 – 1.11]
COVID Trust: National sci/med advisors	1.28 *** [1.20 – 1.35]	1.27 [0.85 – 1.92]	0.99 [0.60 – 1.62]	1.03 [0.69 – 1.51]	1.68 *** [1.24 – 2.30]	0.79 [0.51 – 1.24]	1.08 [0.77 – 1.53]	0.88 [0.61 – 1.28]	1.12 [0.78 – 1.61]	1.02 [0.77 – 1.35]	1.33 [0.97 – 1.83]	1.37 [0.99 – 1.91]
COVID Trust: Independent scientists	0.98 [0.93 – 1.04]	1.08 [0.76 – 1.53]	1.03 [0.69 – 1.51]	0.97 [0.68 – 1.36]	0.77 [0.58 – 1.02]	1.10 [0.78 – 1.54]	1.22 [0.88 – 1.70]	1.25 [0.89 – 1.74]	1.25 [0.89 – 1.74]	1.26 [0.99 – 1.58]	0.95 [0.73 – 1.22]	0.98 [0.77 – 1.23]
COVID Trust: WHO	1.21 *** [1.15 – 1.27]	1.32 [0.93 – 1.85]	1.27 [0.85 – 1.89]	1.05 [0.74 – 1.47]	1.12 [0.84 – 1.49]	1.32 [0.89 – 1.92]	0.86 [0.63 – 1.15]	0.91 [0.66 – 1.23]	1.28 [0.92 – 1.78]	1.60 *** [1.25 – 2.05]	1.09 [0.84 – 1.41]	1.13 [0.88 – 1.45]
Personal efficacy	1.02 [0.98 – 1.07]	1.06 [0.76 – 1.47]	0.96 [0.70 – 1.30]	0.97 [0.71 – 1.32]	0.86 [0.66 – 1.11]	1.16 [0.82 – 1.66]	0.82 [0.62 – 1.07]	0.95 [0.69 – 1.31]	0.83 [0.57 – 1.16]	0.86 [0.66 – 1.10]	0.79 * [0.63 – 0.99]	0.99 [0.80 – 1.22]
Govt efficacy	0.98 [0.92 – 1.05]	0.86 [0.55 – 1.33]	1.41 [0.97 – 2.06]	1.44 [0.96 – 2.20]	0.96 [0.69 – 1.33]	1.25 [0.82 – 1.91]	1.21 [0.81 – 1.81]	1.27 [0.87 – 1.85]	0.94 [0.61 – 1.47]	0.90 [0.67 – 1.21]	0.77 [0.56 – 1.06]	1.11 [0.81 – 1.51]
Perceived infection risk	1.07 ** [1.02 – 1.12]	1.01 [0.74 – 1.37]	1.22 [0.89 – 1.69]	1.20 [0.91 – 1.58]	1.15 [0.91 – 1.45]	1.14 [0.83 – 1.56]	1.22 [0.96 – 1.55]	1.13 [0.84 – 1.50]	1.45 * [1.04 – 2.01]	1.14 [0.91 – 1.41]	1.31 * [1.05 – 1.63]	0.88 [0.71 – 1.08]
Worry about COVID-19	1.37 *** [1.31 – 1.44]	1.52 ** [1.15 – 2.03]	1.41 * [1.05 – 1.91]	1.23 [0.92 – 1.64]	1.21 [0.96 – 1.52]	1.43 * [1.09 – 1.89]	0.99 [0.78 – 1.25]	1.17 [0.88 – 1.53]	1.33 [0.98 – 1.81]	1.26 * [1.01 – 1.57]	1.17 [0.95 – 1.45]	1.59 *** [1.28 – 1.98]
Observations	19248	643	641	669	667	532	590	677	625	683	653	656
R <sup>2</sup> Tjur	0.129	0.109	0.162	0.069	0.136	0.142	0.076	0.073	0.104	0.184	0.113	0.123

Odd ratios [95CI] shown, all continuous measure were standardized (scaled and mean-centered) prior to analysis. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific). <sup>a</sup>Gender is unstandardized. \*p < .05, \*\*p < .01, \*\*\* p < .001

Table S8

Full logistic regression results from model predicting vaccine recommendation to vulnerable others, UK and US samples

	UK_P (Mar) OR	UK_P (May) OR	UK_P (Jul) OR	UK_P (Sep) OR	UK_R (May) OR	UK_R (Jul) OR	UK_R (Sep) OR	UK_R (Oct) OR	US_P (Mar) OR	US_R (May) OR
(Intercept)	16.28 *** [10.45 – 26.82]	15.62 *** [11.10 – 22.65]	10.85 *** [8.19 – 14.66]	6.58 *** [5.39 – 8.10]	8.67 *** [6.49 – 11.82]	8.43 *** [6.45 – 11.22]	6.69 *** [5.45 – 8.30]	5.76 *** [4.71 – 7.11]	11.92 *** [8.03 – 18.40]	8.08 *** [5.62 – 11.97]
Age	1.03 [0.76 – 1.39]	1.32 [0.98 – 1.81]	1.05 [0.86 – 1.30]	1.06 [0.93 – 1.22]	1.33 ** [1.07 – 1.65]	1.54 ** [1.16 – 2.05]	1.49 *** [1.26 – 1.78]	1.39 ** [1.13 – 1.71]	0.84 [0.64 – 1.09]	1.47 [0.97 – 2.23]
Gender (Female)	0.85 [0.46 – 1.55]	0.46 *** [0.30 – 0.69]	0.57 ** [0.40 – 0.82]	0.57 *** [0.44 – 0.74]	0.85 [0.58 – 1.24]	0.91 [0.64 – 1.31]	0.63 *** [0.48 – 0.82]	0.51 *** [0.39 – 0.66]	0.67 [0.40 – 1.12]	0.73 [0.46 – 1.14]
Education	1.21 [0.89 – 1.62]	0.97 [0.79 – 1.18]	1.15 [0.96 – 1.37]	1.02 [0.89 – 1.16]	1.06 [0.87 – 1.29]	1.11 [0.93 – 1.33]	1.04 [0.91 – 1.19]	1.08 [0.95 – 1.24]	1.27 [0.98 – 1.64]	1.26 * [1.00 – 1.60]
Numeracy	1.44 * [1.05 – 2.02]	1.00 [0.82 – 1.22]	1.14 [0.95 – 1.37]	1.14 [1.00 – 1.31]	1.11 [0.92 – 1.35]	0.99 [0.83 – 1.19]	1.06 [0.93 – 1.22]	1.07 [0.94 – 1.22]	1.26 [0.96 – 1.66]	1.35 * [1.06 – 1.73]
Politics (Conservative)	1.04 [0.74 – 1.46]	1.05 [0.84 – 1.32]	1.01 [0.82 – 1.25]	0.88 [0.76 – 1.02]	1.14 [0.92 – 1.41]	1.01 [0.83 – 1.24]	0.98 [0.85 – 1.14]	0.86 * [0.75 – 1.00]	0.81 [0.60 – 1.09]	0.78 [0.59 – 1.05]
Prosociality	0.82 [0.60 – 1.09]	1.23 * [1.01 – 1.50]	1.06 [0.89 – 1.25]	1.07 [0.94 – 1.23]	1.00 [0.82 – 1.22]	1.10 [0.91 – 1.32]	1.06 [0.92 – 1.22]	1.08 [0.94 – 1.24]	0.97 [0.75 – 1.25]	1.18 [0.92 – 1.50]
General social trust	1.05 [0.77 – 1.43]	1.09 [0.87 – 1.36]	1.12 [0.92 – 1.37]	1.08 [0.94 – 1.23]	1.12 [0.91 – 1.39]	1.00 [0.82 – 1.22]	1.08 [0.93 – 1.24]	0.98 [0.86 – 1.13]	1.18 [0.89 – 1.58]	0.97 [0.76 – 1.25]
General trust: Experts	1.21 [0.87 – 1.69]	1.62 *** [1.28 – 2.05]	1.28 * [1.05 – 1.55]	1.39 *** [1.19 – 1.62]	1.32 * [1.05 – 1.66]	1.51 *** [1.24 – 1.85]	1.34 *** [1.15 – 1.57]	1.58 *** [1.35 – 1.86]	1.62 ** [1.17 – 2.27]	1.35 [0.99 – 1.84]
General trust:Govt	1.36 [0.90 – 2.06]	0.85 [0.64 – 1.13]	1.20 [0.93 – 1.53]	1.14 [0.96 – 1.37]	1.11 [0.86 – 1.44]	1.18 [0.92 – 1.51]	1.19 [0.98 – 1.44]	0.95 [0.79 – 1.13]	0.78 [0.55 – 1.08]	0.90 [0.66 – 1.22]
COVID trust: Politicians	0.92 [0.55 – 1.53]	1.28 [0.91 – 1.83]	0.97 [0.71 – 1.32]	1.04 [0.84 – 1.30]	1.00 [0.73 – 1.36]	0.80 [0.57 – 1.13]	1.00 [0.79 – 1.28]	1.33 * [1.06 – 1.68]	1.19 [0.77 – 1.81]	1.10 [0.77 – 1.57]
COVID Trust: National sci/med advisors	1.36 [0.90 – 2.07]	1.41 * [1.07 – 1.85]	1.26 * [1.00 – 1.58]	1.08 [0.91 – 1.29]	1.16 [0.88 – 1.52]	1.20 [0.91 – 1.58]	1.43 *** [1.17 – 1.74]	1.22 * [1.00 – 1.49]	1.09 [0.75 – 1.55]	2.12 *** [1.50 – 3.02]
COVID Trust: Independent scientists	1.17 [0.83 – 1.64]	0.91 [0.72 – 1.15]	0.87 [0.70 – 1.06]	1.03 [0.88 – 1.20]	0.84 [0.65 – 1.07]	1.09 [0.86 – 1.37]	0.85 [0.71 – 1.01]	1.10 [0.93 – 1.30]	1.15 [0.86 – 1.53]	0.80 [0.60 – 1.07]
COVID Trust: WHO	1.05 [0.73 – 1.51]	1.39 ** [1.11 – 1.75]	1.54 *** [1.25 – 1.90]	1.37 *** [1.16 – 1.60]	1.64 *** [1.29 – 2.09]	1.19 [0.94 – 1.51]	1.15 [0.95 – 1.37]	0.91 [0.75 – 1.10]	1.30 [0.96 – 1.75]	1.06 [0.76 – 1.47]
Personal efficacy	1.12 [0.84 – 1.50]	1.11 [0.91 – 1.36]	1.14 [0.95 – 1.35]	1.00 [0.87 – 1.16]	1.02 [0.83 – 1.26]	1.18 [0.96 – 1.43]	1.16 * [1.00 – 1.35]	1.14 [0.99 – 1.32]	1.19 [0.92 – 1.53]	1.14 [0.88 – 1.49]
Govt efficacy	0.88 [0.57 – 1.36]	0.75 [0.56 – 1.01]	1.07 [0.81 – 1.42]	1.03 [0.85 – 1.26]	0.97 [0.74 – 1.28]	1.06 [0.78 – 1.46]	0.90 [0.72 – 1.12]	1.02 [0.83 – 1.25]	0.95 [0.66 – 1.39]	0.90 [0.64 – 1.27]
Perceived infection risk	0.94 [0.69 – 1.28]	1.56 *** [1.25 – 1.94]	1.26 * [1.03 – 1.53]	1.05 [0.91 – 1.22]	1.03 [0.84 – 1.26]	0.93 [0.76 – 1.14]	0.99 [0.85 – 1.15]	1.01 [0.88 – 1.16]	0.98 [0.73 – 1.31]	1.21 [0.92 – 1.58]
Worry about COVID	1.21 [0.89 – 1.62]	1.04 [0.84 – 1.28]	1.13 [0.93 – 1.37]	1.39 *** [1.20 – 1.61]	1.64 *** [1.36 – 1.99]	1.53 *** [1.26 – 1.87]	1.42 *** [1.23 – 1.65]	1.35 *** [1.16 – 1.57]	1.23 [0.92 – 1.64]	1.17 [0.90 – 1.53]
Observations	698	1143	1315	1846	1097	1254	1778	1704	694	683
R <sup>2</sup> Tjur	0.086	0.181	0.169	0.167	0.183	0.183	0.159	0.182	0.2	0.265

Odd ratios [95CI] shown, all continuous measure were standardized (scaled and mean-centered) prior to analysis. For space, samples are defined by their two character ISO country code and a letter denoting participant source (D, Dynata; R, Respondi; P, Prolific). <sup>a</sup>Gender is unstandardized. \*p < .05, \*\*p < .01, \*\*\* p < .001

Table S9

Result of logistic regression models predicting vaccine acceptance, including or excluding general vaccine attitudes.

	Base model			Including general vaccine attitudes		
	UK Prolific (Sep) <i>OR</i>	UK Respondi (Sep) <i>OR</i>	UK Respondi (Oct) <i>OR</i>	UK Prolific (Sep) <i>OR</i>	UK Respondi (Sep) <i>OR</i>	UK Respondi (Oct) <i>OR</i>
(Intercept)	4.16 *** [3.48 – 4.99]	5.55 *** [4.56 – 6.79]	4.94 *** [4.07 – 6.03]	4.29 *** [3.58 – 5.19]	6.18 *** [5.02 – 7.68]	5.40 *** [4.40 – 6.69]
Age	1.12 [0.99 – 1.28]	1.48 *** [1.26 – 1.75]	1.60 *** [1.31 – 1.95]	1.16 * [1.02 – 1.32]	1.40 *** [1.18 – 1.66]	1.41 ** [1.14 – 1.74]
Gender (Female)	0.61 *** [0.48 – 0.78]	0.50 *** [0.39 – 0.65]	0.44 *** [0.34 – 0.57]	0.62 *** [0.48 – 0.79]	0.49 *** [0.38 – 0.64]	0.44 *** [0.33 – 0.57]
Education	1.02 [0.91 – 1.15]	1.11 [0.98 – 1.26]	1.18 * [1.04 – 1.34]	1.00 [0.88 – 1.13]	1.07 [0.94 – 1.23]	1.15 * [1.00 – 1.32]
Numeracy	1.11 [0.98 – 1.26]	1.00 [0.88 – 1.14]	1.00 [0.88 – 1.13]	1.05 [0.93 – 1.19]	0.93 [0.82 – 1.06]	0.87 * [0.76 – 1.00]
Politics (Conservative)	0.84 * [0.74 – 0.97]	0.88 [0.77 – 1.01]	0.86 * [0.74 – 0.98]	0.85 * [0.73 – 0.98]	0.86 [0.75 – 1.00]	0.84 * [0.73 – 0.98]
Prosociality	1.11 [0.98 – 1.26]	1.09 [0.96 – 1.25]	1.07 [0.94 – 1.23]	1.10 [0.96 – 1.25]	1.08 [0.94 – 1.24]	1.04 [0.90 – 1.20]
General social trust	1.03 [0.91 – 1.16]	1.09 [0.95 – 1.25]	0.97 [0.85 – 1.11]	1.03 [0.90 – 1.16]	1.04 [0.90 – 1.20]	0.96 [0.84 – 1.11]
General trust: Experts	1.39 *** [1.21 – 1.61]	1.24 ** [1.06 – 1.44]	1.45 *** [1.24 – 1.69]	1.29 *** [1.11 – 1.50]	1.11 [0.95 – 1.31]	1.29 ** [1.09 – 1.52]
General trust: Govt	1.27 ** [1.07 – 1.50]	1.13 [0.94 – 1.36]	1.02 [0.86 – 1.21]	1.24 * [1.04 – 1.47]	1.15 [0.95 – 1.39]	0.98 [0.82 – 1.18]
COVID trust: Politicians	0.94 [0.77 – 1.14]	1.12 [0.90 – 1.41]	1.26 * [1.02 – 1.57]	0.95 [0.78 – 1.17]	1.18 [0.93 – 1.49]	1.37 ** [1.09 – 1.72]
COVID Trust: National sci/med advisors	1.13 [0.97 – 1.33]	1.25 * [1.04 – 1.50]	1.29 ** [1.07 – 1.56]	1.11 [0.94 – 1.31]	1.14 [0.94 – 1.38]	1.21 [0.98 – 1.48]
COVID Trust: Independent scientists	0.93 [0.80 – 1.07]	0.88 [0.74 – 1.03]	1.00 [0.85 – 1.17]	0.95 [0.82 – 1.10]	0.89 [0.74 – 1.06]	0.96 [0.81 – 1.13]
COVID Trust: WHO	1.45 *** [1.25 – 1.69]	1.33 *** [1.12 – 1.58]	1.03 [0.87 – 1.23]	1.41 *** [1.21 – 1.65]	1.33 ** [1.11 – 1.59]	1.02 [0.85 – 1.24]
Personal efficacy	1.10 [0.96 – 1.25]	1.03 [0.89 – 1.19]	1.03 [0.89 – 1.18]	1.06 [0.93 – 1.22]	1.00 [0.86 – 1.16]	0.98 [0.84 – 1.14]
Govt efficacy	1.01 [0.84 – 1.21]	0.95 [0.77 – 1.16]	1.04 [0.86 – 1.27]	1.01 [0.84 – 1.22]	0.95 [0.77 – 1.18]	1.08 [0.88 – 1.33]
Perceived infection risk	1.04 [0.91 – 1.19]	1.08 [0.94 – 1.25]	0.98 [0.85 – 1.13]	1.02 [0.89 – 1.17]	1.12 [0.96 – 1.30]	0.96 [0.83 – 1.11]
Worry about COVID	1.36 *** [1.19 – 1.57]	1.56 *** [1.35 – 1.80]	1.44 *** [1.24 – 1.66]	1.36 *** [1.18 – 1.56]	1.46 *** [1.26 – 1.70]	1.41 *** [1.20 – 1.65]
General vaccine attitudes				1.69 *** [1.51 – 1.90]	2.10 *** [1.85 – 2.38]	2.31 *** [2.01 – 2.65]
Observations	1847	1778	1704	1841	1773	1700
R <sup>2</sup> Tjur	0.191	0.173	0.193	0.235	0.247	0.281

Odds ratios [95CI] based on standardized (scaled and mean centered) continuous variables except for gender which is unstandardized.

\*p &lt; .05, \*\*p &lt; .01, \*\*\* p &lt; .001